uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.1620 | Q17 | What gene does the drug Tocainide target? | The drug Tocainide targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tocainide%" OR LOWER(tradeNames_string) LIKE "%tocainide%" OR LOWER(drugSynonyms_string) LIKE "%tocainide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5269', 'drugName': 'Tocainide', 'tradeNames_string': '', 'drugSynonyms_string': 'Tocainide, W-36095', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4128', 'drugName': 'Tocainide Hydrochloride', 'tradeNames_string': 'Tonocard, Xylotocan', 'drugSynonyms_string': 'Tocainide hcl, Tocainide hydrochloride, Tocainide monohydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.534 | Q17 | What gene does the drug Doxazosin target? | The drug Doxazosin targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doxazosin%" OR LOWER(tradeNames_string) LIKE "%doxazosin%" OR LOWER(drugSynonyms_string) LIKE "%doxazosin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1652', 'drugName': 'Doxazosin', 'tradeNames_string': '', 'drugSynonyms_string': 'C02CA04, Cardura, Doxazosin, UK-33274', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Erectile Dysfunction (EFO_0004234), Post-Traumatic Stress Disorder (EFO_0001358), Heart Disease (EFO_0003777), Substance Abuse (MONDO_0002491), Drug Dependence (EFO_0003890), Nicotine Dependence (EFO_0003768), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Benign Prostatic Hyperplasia (EFO_0000284), Hypercholesterolemia (HP_0003124), Myocardial Infarction (EFO_0000612), Cocaine Dependence (EFO_0002610), Nephrolithiasis (EFO_0004253), Alcohol Dependence (MONDO_0007079), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_924', 'drugName': 'Doxazosin Mesylate', 'tradeNames_string': 'Cardozin xl, Cardura, Cardura xl, Cascor, Colixil xl, Doxadura, Doxazosin mesylate, Doxzogen xl, Larbex xl, Oxandosin xl, Raporsin xl, Slocinx xl', 'drugSynonyms_string': 'Alfadil, Doxazosin (as mesilate), Doxazosin mesilate, Doxazosin mesylate, Doxazosin methanesulfonate, NSC-759284, UK-33,274-27, UK-33274-27', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Benign Prostatic Hyperplasia (EFO_0000284), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.350 | Q17 | What gene does the drug Pembrolizumab target? | The drug Pembrolizumab targets the gene PDCD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pembrolizumab%" OR LOWER(tradeNames_string) LIKE "%pembrolizumab%" OR LOWER(drugSynonyms_string) LIKE "%pembrolizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5610', 'drugName': 'Pembrolizumab', 'tradeNames_string': 'Keytruda', 'drugSynonyms_string': 'KEYLYNK-010 COMPONENT PEMBROLIZUMAB, Lambrolizumab, MK-3475, PEMBROLIZUMAB COMPONENT OF KEYLYNK-010, Pembrolizumab, SCH-900475', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Malignant Colon Neoplasm (MONDO_0021063), Lymphoid Neoplasm (EFO_0001642), Cervical Adenocarcinoma (EFO_0001416), Papillary Renal Cell Carcinoma (EFO_0000640), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Parotid Gland Cancer (MONDO_0004700), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Viral Pneumonia (EFO_0007541), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrial Neoplasm (EFO_0004230), Cervical Cancer (MONDO_0002974), Follicular Lymphoma (MONDO_0018906), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Anus Cancer (MONDO_0001879), Classic Hodgkin Lymphoma (MONDO_0009348), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Thyroid Gland Undifferentiated (Anaplastic) Carcinoma (EFO_1000595), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Thymic Carcinoma (EFO_1000576), Intraepithelial Neoplasia (MONDO_0024474), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Breast Carcinoma In Situ (MONDO_0004658), Angiosarcoma (EFO_0003968), Neuroendocrine Carcinoma (MONDO_0002120), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Oral Leukoplakia (HP_0002745), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Gastric Adenocarcinoma (EFO_0000503), Bone Sarcoma (MONDO_0021054), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Diffuse Large B-Cell Lymphoma (EFO_0000403), Adult Lymphoma (MONDO_0003660), Metastasis (EFO_0009708), Carcinosarcoma (MONDO_0002928), Small Cell Lung Carcinoma (EFO_0000702), Oropharynx Cancer (EFO_1001931), Head And Neck Neoplasia (EFO_0005950), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Meningeal Neoplasm (EFO_0003851), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Rectum Cancer (EFO_1000657), Metastatic Neoplasm (EFO_0009709), Merkel Cell Skin Cancer (EFO_1001471), Hiv Infection (EFO_0000764), Urogenital Neoplasm (EFO_0003863), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Leukoplakia (MONDO_0043243), Asymptomatic Myeloma (EFO_0003073), Neuroblastoma (EFO_0000621), Head And Neck Carcinoma (MONDO_0002038), Gestational Trophoblastic Neoplasm (MONDO_0018944), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Epithelioid Sarcoma (MONDO_0017387), Ovarian Cancer (MONDO_0008170), Mouth Neoplasm (EFO_0003868), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Female Reproductive System Neoplasm (MONDO_0021148), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Penile Carcinoma (EFO_1000465), Pancreatic Carcinoma (EFO_0002618), Gallbladder Cancer (MONDO_0005411), Neoplasm Of Mature B-Cells (EFO_0000096), Colorectal Cancer (MONDO_0005575), Mesothelioma (EFO_0000588), Skin Carcinoma (EFO_0009259), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Waldenstrom Macroglobulinemia (EFO_0009441), Papilloma (MONDO_0002363), Vulvar Carcinoma (EFO_0002921), Biliary Tract Neoplasm (EFO_0003891), Cutaneous Melanoma (EFO_0000389), Leptomeningeal Metastasis (EFO_1001012), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Stomach Neoplasm (EFO_0003897), Alveolar Soft Part Sarcoma (EFO_0007143), Grade Iii Meningioma (MONDO_0020634), Uterine Cancer (MONDO_0002715), Thyroid Carcinoma (EFO_0002892), Covid-19 (MONDO_0100096), Adenoid Cystic Carcinoma (EFO_0000231), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Cervical Carcinoma (EFO_0001061), Endometrial Carcinoma (EFO_1001512), Esophageal Cancer (MONDO_0007576), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Salivary Gland Carcinoma (MONDO_0000521), Skin Basal Cell Carcinoma (MONDO_0005341), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Skin Neoplasm (EFO_0004198), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Lymphoid Leukemia (EFO_0004289), Anal Carcinoma (MONDO_0003199), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Meningioma (MONDO_0016642), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Pancreatic Neoplasm (EFO_0003860), Pediatric Lymphoma (MONDO_0003659), Bladder Tumor (EFO_0000294)", 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDCD1 (ENSG00000188389)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1389 | Q17 | What gene does the drug Ds-1001B target? | The drug Ds-1001B is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IDH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ds-1001b%" OR LOWER(tradeNames_string) LIKE "%ds-1001b%" OR LOWER(drugSynonyms_string) LIKE "%ds-1001b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5109', 'drugName': 'Ds-1001B', 'tradeNames_string': '', 'drugSynonyms_string': 'DS-1001b, Ds-1001b', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IDH1 (ENSG00000138413)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1961 | Q17 | What gene does the drug Paliperidone Palmitate target? | The drug Paliperidone Palmitate targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%paliperidone palmitate%" OR LOWER(tradeNames_string) LIKE "%paliperidone palmitate%" OR LOWER(drugSynonyms_string) LIKE "%paliperidone palmitate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5388', 'drugName': 'Paliperidone Palmitate', 'tradeNames_string': 'Invega hafyera, Invega sustenna, Invega trinza', 'drugSynonyms_string': 'JNS-010, JNS010, Paliperidone palmitate, Palperidone palmitate, R-092670, R092670, RO-92670, RO92670', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Schizoaffective Disorder (EFO_0005411)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5389', 'drugName': 'Paliperidone Palmitate', 'tradeNames_string': 'Invega hafyera, Invega sustenna, Invega trinza', 'drugSynonyms_string': 'JNS-010, JNS010, Paliperidone palmitate, Palperidone palmitate, R-092670, R092670, RO-92670, RO92670', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Schizoaffective Disorder (EFO_0005411)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1301 | Q17 | What gene does the drug Clonidine target? | The drug Clonidine targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clonidine%" OR LOWER(tradeNames_string) LIKE "%clonidine%" OR LOWER(drugSynonyms_string) LIKE "%clonidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4092', 'drugName': 'Clonidine Hydrochloride', 'tradeNames_string': 'Catapres, Catapres p.l., Catapres tts 1, Catapres tts 2, Catapres tts 3, Clonidine hydrochloride, Dixarit, Duraclon, Jenloga, Kapvay', 'drugSynonyms_string': 'Clonidine hcl, Clonidine hydrochloride, Dichloranilino imidazolin, NSC-756699, ST-155', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Pain (EFO_0003843), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_615', 'drugName': 'Clonidine', 'tradeNames_string': 'Catapres, Catapres-tts-1, Catapres-tts-2, Catapres-tts-3, Clonidine, Nexiclon xr', 'drugSynonyms_string': 'Catapres, Catarpres-tts, Clonidine, Clonidine extended release, Clorpres, Combipres, Duraclon, ST-155-BS, ST-155BS', 'linkedDiseasesDrug_string': 'Fecal Incontinence (EFO_0009523), Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Neonatal Abstinence Syndrome (EFO_0005799), Cannabis Dependence (EFO_0007191), Male Reproductive Organ Cancer (EFO_0007355), Glaucoma (MONDO_0005041), Musculoskeletal System Disease (EFO_0009676), Pregnancy (EFO_0002950), Post-Traumatic Stress Disorder (EFO_0001358), Breast Cancer (MONDO_0007254), Atopic Eczema (EFO_0000274), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Attention Deficit Hyperactivity Disorder (EFO_0003888), Scoliosis (EFO_0004273), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Heroin Dependence (EFO_0004240), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Orthostatic Intolerance (EFO_1000645), Hyperemesis Gravidarum (EFO_1000971), Brain Injury (MONDO_0043510), Opioid Dependence (EFO_0005611), Diabetic Neuropathy (EFO_1000783), Post-Operative Sign Or Symptom (EFO_0005323), Low Back Pain (HP_0003419), Oral Mucositis (EFO_1001904)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2038', 'drugName': 'Apraclonidine Hydrochloride', 'tradeNames_string': 'Apraclonidine hydrochloride, Iopidine', 'drugSynonyms_string': 'AL-02145, AL02145, Aplonidine hydrochloride, Apraclonidine hcl, Apraclonidine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5436', 'drugName': 'Apraclonidine', 'tradeNames_string': 'Iopidine', 'drugSynonyms_string': 'Apraclonidine', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1973 | Q17 | What gene does the drug Becaplermin target? | The drug Becaplermin targets 2 genes: PDGFRB and PDGFRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%becaplermin%" OR LOWER(tradeNames_string) LIKE "%becaplermin%" OR LOWER(drugSynonyms_string) LIKE "%becaplermin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_519', 'drugName': 'Becaplermin', 'tradeNames_string': 'Regranex', 'drugSynonyms_string': 'Becaplermin, GEM 21S, GEM-21S, Gemesis, Pdgf-2, Pdgf-bb, Pdgfb, Platelet derived growth factor-bb, Platelet-derived growth factor becaplermin, RWJ 60235, RWJ-60235, Sh-polypeptide-59', 'linkedDiseasesDrug_string': 'Ulcer Disease (MONDO_0043839), Skin Ulcer (HP_0200042), Diabetic Foot (EFO_1001459)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1980 | Q17 | What gene does the drug Brazikumab target? | The drug Brazikumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: IL12B and IL23A | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brazikumab%" OR LOWER(tradeNames_string) LIKE "%brazikumab%" OR LOWER(drugSynonyms_string) LIKE "%brazikumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1252', 'drugName': 'Brazikumab', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG-139, Brazikumab, MEDI-2070, MEDI2070', 'linkedDiseasesDrug_string': "Ulcerative Colitis (EFO_0000729), Crohn'S Disease (EFO_0000384)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.608 | Q17 | What gene does the drug Choriogonadotropin Alfa target? | The drug Choriogonadotropin Alfa targets the gene LHCGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%choriogonadotropin alfa%" OR LOWER(tradeNames_string) LIKE "%choriogonadotropin alfa%" OR LOWER(drugSynonyms_string) LIKE "%choriogonadotropin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1368', 'drugName': 'Choriogonadotropin Alfa', 'tradeNames_string': 'Ovidrel, Ovitrelle', 'drugSynonyms_string': 'ATC CODE G03 GA GONADOTROPINS, Choriogonadotropin alfa, Choriogonadotropin alpha, Choriongonadotropin alfa, Chorionic gonadotrophin alfa, Fe-999302', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Polycystic Ovary Syndrome (EFO_0000660), Obesity (EFO_0001073), Infertility (EFO_0000545), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Primary Ovarian Insufficiency (EFO_0004266)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LHCGR (ENSG00000138039)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1050 | Q17 | What gene does the drug Fondaparinux target? | The drug Fondaparinux targets the gene SERPINC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fondaparinux%" OR LOWER(tradeNames_string) LIKE "%fondaparinux%" OR LOWER(drugSynonyms_string) LIKE "%fondaparinux%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1957', 'drugName': 'Fondaparinux Sodium', 'tradeNames_string': 'Arixtra, Fondaparinux sodium', 'drugSynonyms_string': 'Fondaparin sodium, Fondaparinux sodium, Fondaparinux sodium for assay, Fondaparinux sodium identification, IC-851589, ORG 31540, ORG-31540, Quixidar, SR 90107A, SR-90107A', 'linkedDiseasesDrug_string': 'Deep Vein Thrombosis (EFO_0003907), Venous Thromboembolism (EFO_0004286), Thromboembolism (HP_0001907), Venous Thrombosis (HP_0004936), Renal Insufficiency (HP_0000083), Pulmonary Embolism (EFO_0003827)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1756', 'drugName': 'Fondaparinux', 'tradeNames_string': '', 'drugSynonyms_string': 'Fondaparinux', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Recurrent Thrombophlebitis (HP_0004419), Thrombocytopenia (HP_0001873), Viral Pneumonia (EFO_0007541), Deep Vein Thrombosis (EFO_0003907), Covid-19 (MONDO_0100096), Respiratory Failure (EFO_0009686), Venous Thromboembolism (EFO_0004286), Acute Coronary Syndrome (EFO_0005672), Thromboembolism (HP_0001907), Venous Thrombosis (HP_0004936), Pulmonary Embolism (EFO_0003827), Renal Insufficiency (HP_0000083), Morbid Obesity (EFO_0001074), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.246 | Q17 | What gene does the drug Dextromoramide target? | The drug Dextromoramide targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dextromoramide%" OR LOWER(tradeNames_string) LIKE "%dextromoramide%" OR LOWER(drugSynonyms_string) LIKE "%dextromoramide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2904', 'drugName': 'Dextromoramide', 'tradeNames_string': '', 'drugSynonyms_string': 'Acscn-9613, Alcoid, Dextromoramide, IDS-ND-003, Jetrium, Linfadol, MCP-875, Moramide, Narcolo, Palfadonna, R-875, Racemoramide, (s)-, SKF-5137, Troxilan, Yetrium', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1681 | Q17 | What gene does the drug Cytisinicline target? | The drug Cytisinicline is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CHRNA4 and CHRNB2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cytisinicline%" OR LOWER(tradeNames_string) LIKE "%cytisinicline%" OR LOWER(drugSynonyms_string) LIKE "%cytisinicline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5551', 'drugName': 'Cytisinicline', 'tradeNames_string': 'Tabex', 'drugSynonyms_string': '6039 Sopharma, Baptitoxine, Cytisine, Cytisinicline, Cytiton, NSC-407282, Sophorine, Ulexine', 'linkedDiseasesDrug_string': 'Nicotine Dependence (EFO_0003768), Smoking Cessation (EFO_0004319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1799 | Q17 | What gene does the drug Oxyphencyclimine Hydrochloride target? | The drug Oxyphencyclimine Hydrochloride targets 2 genes: CHRM3 and CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxyphencyclimine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%oxyphencyclimine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%oxyphencyclimine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2409', 'drugName': 'Oxyphencyclimine Hydrochloride', 'tradeNames_string': 'Daricon', 'drugSynonyms_string': 'NSC-528449, Oxiphencyclimine chloride, Oxyphencyclimine hcl, Oxyphencyclimine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2410', 'drugName': 'Oxyphencyclimine Hydrochloride', 'tradeNames_string': 'Daricon', 'drugSynonyms_string': 'NSC-528449, Oxiphencyclimine chloride, Oxyphencyclimine hcl, Oxyphencyclimine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1717 | Q17 | What gene does the drug Indecainide target? | The drug Indecainide targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%indecainide%" OR LOWER(tradeNames_string) LIKE "%indecainide%" OR LOWER(drugSynonyms_string) LIKE "%indecainide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_112', 'drugName': 'Indecainide', 'tradeNames_string': '', 'drugSynonyms_string': 'Indecainide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_6337', 'drugName': 'Indecainide Hydrochloride', 'tradeNames_string': 'Decabid', 'drugSynonyms_string': 'Indecainide hcl, Indecainide hydrochloride, LY 135837, LY-135837, LY-135857, Ricainide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.316 | Q17 | What gene does the drug Levobunolol target? | The drug Levobunolol targets 2 genes: ADRB1 and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levobunolol%" OR LOWER(tradeNames_string) LIKE "%levobunolol%" OR LOWER(drugSynonyms_string) LIKE "%levobunolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1444', 'drugName': 'Levobunolol', 'tradeNames_string': '', 'drugSynonyms_string': 'Bunolol, (-)-, Bunolol, (s)-, Levobunolol', 'linkedDiseasesDrug_string': 'Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1443', 'drugName': 'Levobunolol', 'tradeNames_string': '', 'drugSynonyms_string': 'Bunolol, (-)-, Bunolol, (s)-, Levobunolol', 'linkedDiseasesDrug_string': 'Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1552', 'drugName': 'Levobunolol Hydrochloride', 'tradeNames_string': 'Akbeta, Betagan, Levobunolol hydrochloride', 'drugSynonyms_string': 'Levobunolol hcl, Levobunolol hydrochloride, NSC-759158, W 7000A, W-7000A', 'linkedDiseasesDrug_string': 'Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1551', 'drugName': 'Levobunolol Hydrochloride', 'tradeNames_string': 'Akbeta, Betagan, Levobunolol hydrochloride', 'drugSynonyms_string': 'Levobunolol hcl, Levobunolol hydrochloride, NSC-759158, W 7000A, W-7000A', 'linkedDiseasesDrug_string': 'Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.441 | Q17 | What gene does the drug Clobetasol Propionate target? | The drug Clobetasol Propionate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clobetasol propionate%" OR LOWER(tradeNames_string) LIKE "%clobetasol propionate%" OR LOWER(drugSynonyms_string) LIKE "%clobetasol propionate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5376', 'drugName': 'Clobetasol Propionate', 'tradeNames_string': 'Clarelux, Clobaderm, Clobetasol propionate, Clobetasol propionate (emollient), Clobex, Cormax, Dermovate, Dermovate nn, Embeline, Embeline e, Etrivex, Impeklo, Impoyz, Olux, Olux e, Temovate, Temovate e', 'drugSynonyms_string': 'CCI 4725, CCI-4725, Clobecort amex, Clobetasol, Clobetasol 17-propionate, Clobetasol propionate, Dovate, GR 2/925, NSC-758634, Psorex', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Oral Lichen Planus (EFO_0008517), Graft Versus Host Disease (MONDO_0013730), Scleroderma (EFO_1001993), Psoriasis Vulgaris (EFO_1001494), Herpes Labialis (EFO_1001347), Vulvar Lichen Sclerosus (EFO_1000623), Cataract (MONDO_0005129), Atopic Eczema (EFO_0000274), Bullous Pemphigoid (EFO_0007187), Lichen Planus (EFO_1000726), Alopecia Areata (EFO_0004192), Rheumatoid Arthritis (EFO_0000685), Toxic Epidermal Necrolysis (EFO_0004775), Rectum Cancer (EFO_1000657), Colon Adenocarcinoma (EFO_1001949), Lichen Disease (EFO_1000724), Skin Disease (EFO_0000701), Seborrheic Dermatitis (EFO_1000764), Phlebitis (EFO_1001395)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1899 | Q17 | What gene does the drug Avelumab target? | The drug Avelumab targets the gene CD274. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%avelumab%" OR LOWER(tradeNames_string) LIKE "%avelumab%" OR LOWER(drugSynonyms_string) LIKE "%avelumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3138', 'drugName': 'Avelumab', 'tradeNames_string': 'Bavencio', 'drugSynonyms_string': 'Avelumab, MSB-0010682, MSB0010682, MSB0010718C, Msb-0010718c', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Skin Cancer (MONDO_0002898), Thymic Carcinoma (EFO_1000576), Gestational Trophoblastic Neoplasm (MONDO_0018944), Adenoid Cystic Carcinoma (EFO_0000231), Urothelial Carcinoma (EFO_0008528), Urogenital Neoplasm (EFO_0003863), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Breast Carcinoma (EFO_0000305), Angiosarcoma (EFO_0003968), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Neuroendocrine Carcinoma (MONDO_0002120), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Colorectal Neoplasm (EFO_0004142), Gastric Adenocarcinoma (EFO_0000503), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Renal Carcinoma (EFO_0002890), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Malignant Glioma (MONDO_0100342), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Hodgkins Lymphoma (EFO_0000183), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Merkel Cell Skin Cancer (EFO_1001471), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Follicular Lymphoma (MONDO_0018906), Fallopian Tube Cancer (MONDO_0002158), Meningioma (MONDO_0016642), Adenocarcinoma (EFO_0000228), Colorectal Adenocarcinoma (EFO_0000365), Nasopharyngeal Neoplasm (EFO_0004252), Urinary Bladder Cancer (MONDO_0001187), Leiomyosarcoma (EFO_0000564), Esophageal Squamous Cell Carcinoma (EFO_0005922), Melanoma (EFO_0000756), Chordoma (MONDO_0008978), Metastatic Prostate Cancer (EFO_0000196), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD274 (ENSG00000120217)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1637 | Q17 | What gene does the drug Methohexital Sodium target? | The drug Methohexital Sodium targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methohexital sodium%" OR LOWER(tradeNames_string) LIKE "%methohexital sodium%" OR LOWER(drugSynonyms_string) LIKE "%methohexital sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4143', 'drugName': 'Methohexital Sodium', 'tradeNames_string': 'Brevimytal, Brevital, Brevital sodium, Brietal, Brietal sod, Methohexitone', 'drugSynonyms_string': 'Enallynymal sodium, Methohexital sodium, Methohexital sodium salt, Sodium methohexital', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.312 | Q17 | What gene does the drug Medi-565 target? | The drug Medi-565 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CD3E and CEACAM5 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%medi-565%" OR LOWER(tradeNames_string) LIKE "%medi-565%" OR LOWER(drugSynonyms_string) LIKE "%medi-565%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6252', 'drugName': 'Medi-565', 'tradeNames_string': '', 'drugSynonyms_string': 'MEDI-565, Medi-565', 'linkedDiseasesDrug_string': 'Adenocarcinoma (EFO_0000228)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), CD3E (ENSG00000198851)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6253', 'drugName': 'Medi-565', 'tradeNames_string': '', 'drugSynonyms_string': 'MEDI-565, Medi-565', 'linkedDiseasesDrug_string': 'Adenocarcinoma (EFO_0000228)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), CD3E (ENSG00000198851)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.436 | Q17 | What gene does the drug Canertinib Dihydrochloride target? | The drug Canertinib Dihydrochloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: ERBB2, ERBB4 and EGFR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%canertinib dihydrochloride%" OR LOWER(tradeNames_string) LIKE "%canertinib dihydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%canertinib dihydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4700', 'drugName': 'Canertinib Dihydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib dihydrochloride, Canertinib hydrochloride, PD-0183805, PD-0183805-002B, PD-183805, SN-26606', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4701', 'drugName': 'Canertinib Dihydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib dihydrochloride, Canertinib hydrochloride, PD-0183805, PD-0183805-002B, PD-183805, SN-26606', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4702', 'drugName': 'Canertinib Dihydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-1033, Canertinib dihydrochloride, Canertinib hydrochloride, PD-0183805, PD-0183805-002B, PD-183805, SN-26606', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Lung Neoplasm (MONDO_0021117), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.667 | Q17 | What gene does the drug Bisoprolol Fumarate target? | The drug Bisoprolol Fumarate targets the gene ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bisoprolol fumarate%" OR LOWER(tradeNames_string) LIKE "%bisoprolol fumarate%" OR LOWER(drugSynonyms_string) LIKE "%bisoprolol fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5408', 'drugName': 'Bisoprolol Fumarate', 'tradeNames_string': 'Bipranix, Bisoprolol fumarate, Cardicor, Concor, Congescor, Emcor, Emcor ls, Isoten mitis, Monocor, Soloc, Soprol, Vivacor, Zebeta', 'drugSynonyms_string': 'Bisoprolol fumarate, Bisoprolol hemifumarate, CL 297,939, CL-297939, Detensiel, EMD-33-512, EMD-33512, Emconcor, Euradal, Isoten, Speridol', 'linkedDiseasesDrug_string': 'Fish-Eye Disease (Orphanet_79292), Duchenne Muscular Dystrophy (MONDO_0010679), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.376 | Q17 | What gene does the drug Raf-265 target? | The drug Raf-265 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: KDR and BRAF | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%raf-265%" OR LOWER(tradeNames_string) LIKE "%raf-265%" OR LOWER(drugSynonyms_string) LIKE "%raf-265%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4228', 'drugName': 'Raf-265', 'tradeNames_string': '', 'drugSynonyms_string': 'CHIR-265, NVP-RAF265, RAF265, Raf 265, Raf-265', 'linkedDiseasesDrug_string': 'Metastatic Melanoma (EFO_0002617), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), KDR (ENSG00000128052)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4229', 'drugName': 'Raf-265', 'tradeNames_string': '', 'drugSynonyms_string': 'CHIR-265, NVP-RAF265, RAF265, Raf 265, Raf-265', 'linkedDiseasesDrug_string': 'Metastatic Melanoma (EFO_0002617), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), KDR (ENSG00000128052)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.572 | Q17 | What gene does the drug Gemcitabine target? | The drug Gemcitabine targets 14 genes: POLD3, RRM2B, POLD1, POLE, POLD4, POLD2, PRIM2, RRM1, POLA1, PRIM1, RRM2, POLE3, POLA2 and POLE2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gemcitabine%" OR LOWER(tradeNames_string) LIKE "%gemcitabine%" OR LOWER(drugSynonyms_string) LIKE "%gemcitabine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_string': 'Gemcitabine hydrochloride, Gemzar, Infugem', 'drugSynonyms_string': 'Gemcitabine (as hydrochloride), Gemcitabine hcl, Gemcitabine hydrochloride, Gemzar, LY-188011, LY-188011 HYDROCHLORIDE, LY188011 HYDROCHLORIDE', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Ureter Cancer (MONDO_0008627), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Hilar Cholangiocarcinoma (EFO_1001959), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Thromboembolism (HP_0001907), Mycosis Fungoides (EFO_1001051), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Gallbladder Cancer (MONDO_0005411), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Uterine Carcinosarcoma (EFO_1000613), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Urinary Bladder Cancer (MONDO_0001187), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'numberLinkedTargets': 14}, {'UUID': 'DrugGeneTargets_v2_4', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_string': 'Gemcitabine hydrochloride, Gemzar, Infugem', 'drugSynonyms_string': 'Gemcitabine (as hydrochloride), Gemcitabine hcl, Gemcitabine hydrochloride, Gemzar, LY-188011, LY-188011 HYDROCHLORIDE, LY188011 HYDROCHLORIDE', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Ureter Cancer (MONDO_0008627), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Hilar Cholangiocarcinoma (EFO_1001959), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Thromboembolism (HP_0001907), Mycosis Fungoides (EFO_1001051), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Gallbladder Cancer (MONDO_0005411), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Uterine Carcinosarcoma (EFO_1000613), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Urinary Bladder Cancer (MONDO_0001187), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'numberLinkedTargets': 14}, {'UUID': 'DrugGeneTargets_v2_66', 'drugName': 'Gemcitabine', 'tradeNames_string': 'Gemzar', 'drugSynonyms_string': 'Gemcitabine, Gemzar, LY-188011, LY188011, NSC-613327', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Gallbladder Carcinoma (EFO_1001956), Biliary Tract Disease (EFO_0009534), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Osteosarcoma (EFO_0000637), Leukemia (EFO_0000565), Ewing Sarcoma (EFO_0000174), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lung Cancer (MONDO_0008903), Leiomyosarcoma (EFO_0000564), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Classic Hodgkin Lymphoma (MONDO_0009348), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Colorectal Carcinoma (EFO_1001951), Hilar Cholangiocarcinoma (EFO_1001959), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Uterine Neoplasm (EFO_0003859), Bone Sarcoma (MONDO_0021054), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Large Cell Lung Carcinoma (EFO_0003050), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Hepatoblastoma (EFO_1000292), Gastric Cancer (MONDO_0001056), Gastrointestinal Disease (EFO_0010282), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Gallbladder Cancer (MONDO_0005411), Colorectal Cancer (MONDO_0005575), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Gallbladder Neoplasm (EFO_0004606), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Urinary Bladder Cancer (MONDO_0001187), Testicular Carcinoma (EFO_0005088), Uterine Carcinosarcoma (EFO_1000613), Adenocarcinoma (EFO_0000228), Sarcoma (EFO_0000691), Synovial Sarcoma (EFO_0001376), Lymphoproliferative Syndrome (MONDO_0016537), Medulloblastoma (EFO_0002939), Ureter Cancer (MONDO_0008627), Peritoneal Neoplasm (EFO_1001100), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Bile Duct Cancer (MONDO_0003059), Male Breast Carcinoma (EFO_0006861), Cervical Carcinoma (EFO_0001061), Thromboembolism (HP_0001907), Urethra Cancer (MONDO_0004192), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'numberLinkedTargets': 14}, {'UUID': 'DrugGeneTargets_v2_65', 'drugName': 'Gemcitabine', 'tradeNames_string': 'Gemzar', 'drugSynonyms_string': 'Gemcitabine, Gemzar, LY-188011, LY188011, NSC-613327', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Gallbladder Carcinoma (EFO_1001956), Biliary Tract Disease (EFO_0009534), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Osteosarcoma (EFO_0000637), Leukemia (EFO_0000565), Ewing Sarcoma (EFO_0000174), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lung Cancer (MONDO_0008903), Leiomyosarcoma (EFO_0000564), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Classic Hodgkin Lymphoma (MONDO_0009348), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Colorectal Carcinoma (EFO_1001951), Hilar Cholangiocarcinoma (EFO_1001959), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Uterine Neoplasm (EFO_0003859), Bone Sarcoma (MONDO_0021054), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Large Cell Lung Carcinoma (EFO_0003050), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Hepatoblastoma (EFO_1000292), Gastric Cancer (MONDO_0001056), Gastrointestinal Disease (EFO_0010282), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Gallbladder Cancer (MONDO_0005411), Colorectal Cancer (MONDO_0005575), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Gallbladder Neoplasm (EFO_0004606), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Urinary Bladder Cancer (MONDO_0001187), Testicular Carcinoma (EFO_0005088), Uterine Carcinosarcoma (EFO_1000613), Adenocarcinoma (EFO_0000228), Sarcoma (EFO_0000691), Synovial Sarcoma (EFO_0001376), Lymphoproliferative Syndrome (MONDO_0016537), Medulloblastoma (EFO_0002939), Ureter Cancer (MONDO_0008627), Peritoneal Neoplasm (EFO_1001100), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Bile Duct Cancer (MONDO_0003059), Male Breast Carcinoma (EFO_0006861), Cervical Carcinoma (EFO_0001061), Thromboembolism (HP_0001907), Urethra Cancer (MONDO_0004192), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'numberLinkedTargets': 14}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1226 | Q17 | What gene does the drug Ex-527 target? | The drug Ex-527 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SIRT1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ex-527%" OR LOWER(tradeNames_string) LIKE "%ex-527%" OR LOWER(drugSynonyms_string) LIKE "%ex-527%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2011', 'drugName': 'Ex-527', 'tradeNames_string': '', 'drugSynonyms_string': 'Ex-527', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SIRT1 (ENSG00000096717)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.184 | Q17 | What gene does the drug Belimumab target? | The drug Belimumab targets the gene TNFSF13B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%belimumab%" OR LOWER(tradeNames_string) LIKE "%belimumab%" OR LOWER(drugSynonyms_string) LIKE "%belimumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6001', 'drugName': 'Belimumab', 'tradeNames_string': 'Benlysta, Lymphostat-b, Lymphostat-b benlysta', 'drugSynonyms_string': 'BEL-114333, BEL114333, Belimumab, Belimumab (genetical recombination), GSK-1550188, GSK1550188, HGS-1006, HGS1006', 'linkedDiseasesDrug_string': 'Nephrotic Syndrome (EFO_0004255), Lymphopenia (MONDO_0003783), Chronic Lymphocytic Leukemia (EFO_0000095), Immune System Disease (EFO_0000540), Systemic Scleroderma (EFO_0000717), Multiple Sclerosis (MONDO_0005301), Sjogren Syndrome (EFO_0000699), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Graft Versus Host Disease (MONDO_0013730), Neuromyelitis Optica (EFO_0004256), Emphysema (EFO_0000464), Vasculitis (EFO_0006803), Systemic Lupus Erythematosus (MONDO_0007915), Myositis (EFO_0000783), Rheumatoid Arthritis (EFO_0000685), Antiphospholipid Syndrome (EFO_0002689), Lupus Nephritis (EFO_0005761), Membranous Glomerulonephritis (EFO_0004254)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFSF13B (ENSG00000102524)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1115 | Q17 | What gene does the drug Eflornithine Hydrochloride target? | The drug Eflornithine Hydrochloride targets the gene ODC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eflornithine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%eflornithine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%eflornithine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1880', 'drugName': 'Eflornithine Hydrochloride', 'tradeNames_string': 'Ornidyl, Vaniqa', 'drugSynonyms_string': 'Dfmo hcl, Difluromethylornithine, Eflornithine hcl, Eflornithine hydrochloride, Eflornithine hydrochloride monohydrate, MDL 71,782 A, MDL-71782-A, MDL-71782A, NSC-270295, NSC-337250, RMI-71782-A', 'linkedDiseasesDrug_string': 'Familial Adenomatous Polyposis (Orphanet_733), Neuroblastoma (EFO_0000621)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ODC1 (ENSG00000115758)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.628 | Q17 | What gene does the drug Paramethasone Acetate target? | The drug Paramethasone Acetate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%paramethasone acetate%" OR LOWER(tradeNames_string) LIKE "%paramethasone acetate%" OR LOWER(drugSynonyms_string) LIKE "%paramethasone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2298', 'drugName': 'Paramethasone Acetate', 'tradeNames_string': 'Haldrone', 'drugSynonyms_string': 'Dillar, Paramethasone, Paramethasone 21-acetate, Paramethasone acetate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1910 | Q17 | What gene does the drug Mycophenolate Mofetil Hydrochloride target? | The drug Mycophenolate Mofetil Hydrochloride targets 2 genes: IMPDH2 and IMPDH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mycophenolate mofetil hydrochloride%" OR LOWER(tradeNames_string) LIKE "%mycophenolate mofetil hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%mycophenolate mofetil hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4489', 'drugName': 'Mycophenolate Mofetil Hydrochloride', 'tradeNames_string': 'Cellcept, Mycophenolate mofetil hydrochloride', 'drugSynonyms_string': 'Mycophenolate mofetil hcl, Mycophenolate mofetil hydrochloride, RS-61443-190', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IMPDH1 (ENSG00000106348), IMPDH2 (ENSG00000178035)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1192 | Q17 | What gene does the drug Alfuzosin target? | The drug Alfuzosin targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alfuzosin%" OR LOWER(tradeNames_string) LIKE "%alfuzosin%" OR LOWER(drugSynonyms_string) LIKE "%alfuzosin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1235', 'drugName': 'Alfuzosin Hydrochloride', 'tradeNames_string': 'Alfutral sr, Alfuzosin hydrochloride, Benestan, Benestan ret, Besavar xl, Fuzatal xl, Kelanu xl, Urion s, Uroxatral, Vasran xl, Xatral, Xatral sr, Zufal xl', 'drugSynonyms_string': 'Alfuzosin hcl, Alfuzosin hydrochloride, SL 77 499-10, SL-77-499-10, SL-77499-10', 'linkedDiseasesDrug_string': 'Ureterolithiasis (EFO_1001228), Nephrolithiasis (EFO_0004253), Benign Prostatic Hyperplasia (EFO_0000284)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3084', 'drugName': 'Alfuzosin', 'tradeNames_string': '', 'drugSynonyms_string': 'Alfuzosin, NSC-760065, Uroxatral', 'linkedDiseasesDrug_string': 'Urinary Retention (HP_0000016), Multiple Sclerosis (MONDO_0005301), Benign Prostatic Hyperplasia (EFO_0000284), Prostatitis (EFO_0003830), Constipation (HP_0002019), Nephrolithiasis (EFO_0004253), Neurogenic Bladder (HP_0000011), Ureterolithiasis (EFO_1001228)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.940 | Q17 | What gene does the drug Cyclizine target? | The drug Cyclizine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cyclizine%" OR LOWER(tradeNames_string) LIKE "%cyclizine%" OR LOWER(drugSynonyms_string) LIKE "%cyclizine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4766', 'drugName': 'Cyclizine', 'tradeNames_string': '', 'drugSynonyms_string': 'Cyclizine, Marezine, NSC-26608', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_954', 'drugName': 'Cyclizine Lactate', 'tradeNames_string': 'Marezine', 'drugSynonyms_string': 'Cyclizine lactate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1774 | Q17 | What gene does the drug Testosterone target? | The drug Testosterone targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testosterone%" OR LOWER(tradeNames_string) LIKE "%testosterone%" OR LOWER(drugSynonyms_string) LIKE "%testosterone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_939', 'drugName': 'Testosterone Undecanoate', 'tradeNames_string': 'Andriol, Aveed, Jatenzo, Kyzatrex, Nebido, Restandol, Restandol testocap, Tlando, Undestor', 'drugSynonyms_string': 'Kyzatrex, MK-3033, ORG 538, ORG-538, TSX-011, Testosterone 17.beta.-undecylate, Testosterone undecanoate, Testosterone undecylate, Testosterone, undecanoate (ester), Tlando', 'linkedDiseasesDrug_string': "Hypogonadism (MONDO_0002146), Coronary Artery Disease (EFO_0001645), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Respiratory Failure (EFO_0009686), Renal Cell Carcinoma (EFO_0000681), Klinefelter'S Syndrome (EFO_1001006), Hypogonadotropic Hypogonadism (MONDO_0018555), Aging (GO_0007568), Malnutrition (EFO_0008572), Sexual Dysfunction (EFO_0004714), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078)", 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2128', 'drugName': 'Testosterone Propionate', 'tradeNames_string': 'Testosterone propionate', 'drugSynonyms_string': 'NRB-03689, NSC-9166, Orchisterone, Testosteron 17-propionate, Testosterone 17.beta.-propionate, Testosterone Propionate, Testosterone propionate, Testosterone propionate ciii, Testosteroni propionas, Virormone', 'linkedDiseasesDrug_string': 'Atrophic Vaginitis (EFO_1001271)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2855', 'drugName': 'Norethindrone Acetate', 'tradeNames_string': 'Aygestin, Norethidrone Acetate, Norethindrone acetate, Norlutate', 'drugSynonyms_string': 'NSC-22844, Norethindrone acetate, Norethisteron acetate, Norethisterone 17-acetate, Norethisterone acetate, Norethisteroni acetas, Norethynyltestosterone, Norlutin acetate, SH-420', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Breast Cancer (MONDO_0007254), Hemorrhage (MP_0001914), Pain (EFO_0003843), Premature Ovarian Insufficiency (HP_0008209), Uterine Fibroid (EFO_0000731), Lymphoma (EFO_0000574), Endometriosis (EFO_0001065), Cystic Fibrosis (MONDO_0009061), Acne (EFO_0003894), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5308', 'drugName': 'Testosterone', 'tradeNames_string': 'Androderm, Androgel, Androgel 1%, Andropatch, Axiron, Fortesta, Intrinsa, Natesto, Striant, Striant sr, Testim, Testim 1%, Testoderm, Testoderm tts, Testogel, Testopatch, Testopel, Testoral, Testosterone, Tostran, Vogelxo', 'drugSynonyms_string': 'Delatestryl, NSC-9700, TESTIM, Testosterone, Testosterone ciii', 'linkedDiseasesDrug_string': "Erectile Dysfunction (EFO_0004234), Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Coronary Artery Disease (EFO_0001645), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Aids (EFO_0000765), Hypogonadotropic Hypogonadism (MONDO_0018555), Klinefelter'S Syndrome (EFO_1001006), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Prostate Carcinoma (EFO_0001663), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Growth Delay (HP_0001510), Muscular Disease (EFO_0002970), Hypogonadotropic Hypogonadism (HP_0000044), Sexual Dysfunction (EFO_0004714), Hypogonadism (MONDO_0002146), Insulin Resistance (EFO_0002614), Abnormality Of Connective Tissue (HP_0003549), Sarcopenia (EFO_1000653), Menopause (EFO_0003922), Infertility (EFO_0000545), Chronic Kidney Disease (EFO_0003884), Kallmann Syndrome (MONDO_0018800), Testicular Carcinoma (EFO_0005088), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195), Dyspareunia (HP_0030016), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Genetic Disorder Of Sex Development (Orphanet_325690)", 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5959', 'drugName': 'Testosterone Enanthate', 'tradeNames_string': 'Delatestryl, Primoteston depot, Testosterone enanthate, Xyosted (autoinjector)', 'drugSynonyms_string': 'Androtardyl, NSC-17591, Testosterone enantate, Testosterone enanthate, Testosterone enanthate ciii, Testosterone heptanoate, Testosteroni enantas, Xyosted', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Prostate Cancer (MONDO_0008315), Hypogonadotropic Hypogonadism (HP_0000044), Metastatic Prostate Cancer (EFO_0000196), Chronic Obstructive Pulmonary Disease (EFO_0000341), Weight Loss (HP_0001824), Hiv Wasting Syndrome (EFO_0007312), Facioscapulohumeral Dystrophy (Orphanet_269), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4237', 'drugName': 'Nandrolone Phenpropionate', 'tradeNames_string': 'Durabolin, Nandrolone phenpropionate', 'drugSynonyms_string': 'Nandrolone phenpropionate, Nandrolone phenylpropionate, Norandrostenolone phenylpropionate, Nortestosterone furanpropionate, Nortestosterone phenylpropionate', 'linkedDiseasesDrug_string': 'Eye Disease (EFO_0003966)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_434', 'drugName': 'Testosterone Cypionate', 'tradeNames_string': 'Andro-Cyp, Depandro, Depo-testosterone, Depotest, Testosterone, Testosterone cypionate', 'drugSynonyms_string': 'Depo-Testadiol, NSC-9157, Testosterone 17.beta.-cyclopentanepropionate, Testosterone cipionate, Testosterone cyclopentylpropionate, Testosterone cypionate, Testosterone cypionate ciii', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Prostate Cancer (MONDO_0008315), Diabetic Neuropathy (EFO_1000783), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Sexual Dysfunction (EFO_0004714), Prostate Adenocarcinoma (EFO_0000673), Orchitis (EFO_1001078)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2216', 'drugName': 'Methyltestosterone', 'tradeNames_string': 'Android 10, Android 25, Android 5, Metandren, Methitest, Methyltestosterone, Oreton, Oreton methyl, Perandren, Plex hormone, Potensan fte, Testovis, Testred, Virilon', 'drugSynonyms_string': '17-methyltestosterone, CDB-110, L 589.372, L-589.372, L-589372, Methyltestosterone, Methyltestosterone ciii, NSC-139965, NSC-9701, Oxandrolone impurity, methyltestosterone-, RU 24400, RU-24400, U-2842', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Menopause (EFO_0003922), Breast Cancer (MONDO_0007254), Orchitis (EFO_1001078)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1842 | Q17 | What gene does the drug Dexamethasone Sodium Phosphate target? | The drug Dexamethasone Sodium Phosphate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexamethasone sodium phosphate%" OR LOWER(tradeNames_string) LIKE "%dexamethasone sodium phosphate%" OR LOWER(drugSynonyms_string) LIKE "%dexamethasone sodium phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3466', 'drugName': 'Dexamethasone Sodium Phosphate', 'tradeNames_string': 'Decadron, Dexacen-4, Dexacort, Dexair, Dexamethasone, Dexamethasone sodium phosphate, Dexamethasone sodium phosphate preservative free, Hexadrol, Maxidex', 'drugSynonyms_string': 'Dexamethasone 21-phosphate disodium salt, Dexamethasone sodium phosphate, NSC-756722, TLC-399, TLC399, Tlc399', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Ankylosing Spondylitis (EFO_0003898), Allergic Rhinitis (EFO_0005854), Eosinophilic Pneumonia (EFO_0007257), Iridocyclitis (HP_0001094), Corneal Scarring (HP_0000559), Lymphoid Neoplasm (EFO_0001642), Pemphigus Vulgaris (EFO_0004719), Seasonal Allergic Rhinitis (EFO_0003956), Dermatitis Herpetiformis (EFO_1000684), Atopic Eczema (EFO_0000274), Aplastic Anemia (HP_0001915), Keratitis (EFO_0009449), Primary Adrenal Insufficiency (MONDO_0015128), Optic Neuritis (EFO_0007405), Hemolytic Anemia (EFO_0005558), Choroiditis (MONDO_0001280), Gout (EFO_0004274), Iritis (EFO_1000997), Leukemia (EFO_0000565), Adrenocortical Insufficiency (EFO_0009491), Myocarditis (EFO_0009609), Cancer (MONDO_0004992), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Sympathetic Ophthalmia (EFO_1001205), Pulmonary Tuberculosis (EFO_1000049), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), Arthropathy (HP_0003040), Peptic Ulcer (HP_0004398), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Hemorrhoid (EFO_0009552), Spinal Stenosis (EFO_0007490), Influenza (EFO_0007328), Osteoarthritis (MONDO_0005178), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Posterior Uveitis (EFO_1001119), Ischemia (EFO_0000556), Dermatitis (MONDO_0002406), Chorioretinitis (HP_0012424), Peripheral Arterial Disease (EFO_0004265), Plasmacytoma (EFO_0006738), Rotator Cuff Tear (EFO_1001250), Juvenile Idiopathic Arthritis (EFO_0002609), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Frozen Shoulder (EFO_1000941), Adrenal Gland Disease (EFO_0005539), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Mycosis Fungoides (EFO_1001051), Acne (EFO_0003894), Tenosynovitis (EFO_1001435), Hypercalcemia (HP_0003072), Exfoliative Dermatitis (EFO_0009456), Contact Dermatitis (EFO_0005319), Brain Edema (EFO_1000845), Erythema Multiforme (EFO_1000694), Sarcoidosis (MONDO_0019338), Ophthalmic Herpes Zoster (EFO_0007403), Herpes Simplex Infection (EFO_1002022), Seborrheic Dermatitis (EFO_1000764), Lateral Epicondylitis (EFO_1001896), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Stevens-Johnson Syndrome (EFO_0004276), Ulcerative Colitis (EFO_0000729), Nephrotic Syndrome (EFO_0004255), Crohn'S Disease (EFO_0000384), Eye Inflammation (EFO_0005752), Thrombocytopenia (HP_0001873), Synovitis (EFO_0008997), Inflammation (MP_0001845), Meningeal Tuberculosis (EFO_1000039), Rheumatoid Arthritis (EFO_0000685), Nasal Congestion (HP_0001742), Subacute Thyroiditis (EFO_1001194), Macular Retinal Edema (MONDO_0003005), Trichinosis (EFO_0007520), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1331 | Q17 | What gene does the drug Futibatinib target? | The drug Futibatinib targets 4 genes: FGFR2, FGFR1, FGFR3 and FGFR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%futibatinib%" OR LOWER(tradeNames_string) LIKE "%futibatinib%" OR LOWER(drugSynonyms_string) LIKE "%futibatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6327', 'drugName': 'Futibatinib', 'tradeNames_string': 'Lytgobi', 'drugSynonyms_string': 'Fgfr-in-1, Futibatinib, TAS-120, Tas 120, Tas-120', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Cholangiocarcinoma (EFO_0005221)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.300 | Q17 | What gene does the drug Insulin Glargine target? | The drug Insulin Glargine targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin glargine%" OR LOWER(tradeNames_string) LIKE "%insulin glargine%" OR LOWER(drugSynonyms_string) LIKE "%insulin glargine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_495', 'drugName': 'Insulin Glargine', 'tradeNames_string': 'Abasaglar, Abasaglar kwikpen, Basaglar, Ins lantus, Ins lantus opticlik, Ins lantus optiset, Ins lantus solostar, Lantus, Lantus solostar, Toujeo, Toujeo max solostar, Toujeo solostar', 'drugSynonyms_string': 'Basalin, Basalog, Galactus, Glargin, Glargine, Glaricon, HOE 71GT, HOE 901, HOE-71GT, HOE-901, Insulin Glargine Recombinant, Insulin glargine, Insulin glargine recombinant, Insulin glargine yfgn, Insulin glargine-yfgn, LY-2963016, LY2963016, Lantus r, Lusduna, MK-1293, MYL-1501D, Myl-1501d, Semglee', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperglycemia (HP_0003074), Coronary Artery Disease (EFO_0001645), Diabetic Ketoacidosis (EFO_1000897), Leukemia (EFO_0000565), Diabetic Retinopathy (EFO_0003770), Hypertension (EFO_0000537), Lymphoma (EFO_0000574), Hypercholesterolemia (HP_0003124), Myocardial Infarction (EFO_0000612), Prediabetes Syndrome (EFO_1001121), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1619 | Q17 | What gene does the drug Fasitibant Chloride target? | The drug Fasitibant Chloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene BDKRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fasitibant chloride%" OR LOWER(tradeNames_string) LIKE "%fasitibant chloride%" OR LOWER(drugSynonyms_string) LIKE "%fasitibant chloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1160', 'drugName': 'Fasitibant Chloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Fasitibant chloride, Men16132', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'BDKRB2 (ENSG00000168398)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.467 | Q17 | What gene does the drug Alprazolam target? | The drug Alprazolam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alprazolam%" OR LOWER(tradeNames_string) LIKE "%alprazolam%" OR LOWER(drugSynonyms_string) LIKE "%alprazolam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4460', 'drugName': 'Alprazolam', 'tradeNames_string': 'Alprazolam, Niravam, Xanax, Xanax xr', 'drugSynonyms_string': 'Alprazolam, Alprazolam civ, NSC-760140, U 31,889, U-31,889, U-31889', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Asthma (MONDO_0004979), Drug Dependence (EFO_0003890), Anxiety Disorder (EFO_0006788), Seizure (HP_0001250), Migraine Disorder (MONDO_0005277), Dementia (HP_0000726), Anxiety (EFO_0005230), Generalized Anxiety Disorder (EFO_1001892), Panic Disorder (EFO_0004262), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Type 1 Diabetes Mellitus (MONDO_0005147), Social Anxiety Disorder (EFO_1001917), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1302 | Q17 | What gene does the drug Idarubicin target? | The drug Idarubicin targets the gene TOP2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%idarubicin%" OR LOWER(tradeNames_string) LIKE "%idarubicin%" OR LOWER(drugSynonyms_string) LIKE "%idarubicin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5440', 'drugName': 'Idarubicin Hydrochloride', 'tradeNames_string': 'Idamycin, Idamycin pfs, Idarubicin hydrochloride, Idarubicin hydrochloride pfs, Zavedos', 'drugSynonyms_string': 'IMI 30, IMI-30, Idarubicin hcl, Idarubicin hydrochloride, NSC-256439', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Acute Myeloid Leukemia (EFO_0000222), Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_459', 'drugName': 'Idarubicin', 'tradeNames_string': '', 'drugSynonyms_string': 'Idamycin, Idarubicin', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Myeloid Leukemia (MONDO_0004643), Refractory Anemia (EFO_0003802), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Chronic Myelogenous Leukemia (EFO_0000339), Acute Promyelocytic Leukemia (EFO_0000224), Acute Erythroblastic Leukemia (EFO_1001257), Hepatocellular Carcinoma (EFO_0000182), Acute Myelomonocytic Leukemia (EFO_0000223), Neutropenia (MONDO_0001475), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Lymphoma (EFO_0000574), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Acute Megakaryoblastic Leukaemia (EFO_0003025), Refractory Anemia With Excess Blasts (EFO_0003811), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Acute Erythroleukemia (EFO_0000218), Liver Cancer (MONDO_0002691), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Leukemia (EFO_0000565), Acute Monocytic Leukemia (EFO_0000221)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1250 | Q17 | What gene does the drug Clx-0921 target? | The drug Clx-0921 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PPARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clx-0921%" OR LOWER(tradeNames_string) LIKE "%clx-0921%" OR LOWER(drugSynonyms_string) LIKE "%clx-0921%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5833', 'drugName': 'Clx-0921', 'tradeNames_string': '', 'drugSynonyms_string': 'Clx-0921, THR-0921', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.383 | Q17 | What gene does the drug Nisoldipine target? | The drug Nisoldipine targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nisoldipine%" OR LOWER(tradeNames_string) LIKE "%nisoldipine%" OR LOWER(drugSynonyms_string) LIKE "%nisoldipine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5409', 'drugName': 'Nisoldipine', 'tradeNames_string': 'Nisoldipine, Sular, Syscor mr 10, Syscor mr 20, Syscor mr 30', 'drugSynonyms_string': 'BAY K 5552, BAY-K-5552, Baymycard, Geomatrix 16e, NSC-759106, Nisoldipin, Nisoldipine, Nisoldipine (stn)', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1768 | Q17 | What gene does the drug Polyestradiol Phosphate target? | The drug Polyestradiol Phosphate targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%polyestradiol phosphate%" OR LOWER(tradeNames_string) LIKE "%polyestradiol phosphate%" OR LOWER(drugSynonyms_string) LIKE "%polyestradiol phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5051', 'drugName': 'Polyestradiol Phosphate', 'tradeNames_string': 'Estradurin, Polyest phos', 'drugSynonyms_string': 'Estradiol phosphate polymer, LEO 114, LEO-114, Polyestradiol phos phosphate, Polyestradiol phosphate', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.108 | Q17 | What gene does the drug Trastuzumab target? | The drug Trastuzumab targets the gene ERBB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trastuzumab%" OR LOWER(tradeNames_string) LIKE "%trastuzumab%" OR LOWER(drugSynonyms_string) LIKE "%trastuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3205', 'drugName': 'Trastuzumab Deruxtecan', 'tradeNames_string': 'Enhertu', 'drugSynonyms_string': 'DS-8201, DS-8201a, Ds-8201a, Fam-trastuzumab deruxtecan-nxki, Trastuzumab deruxtecan, Trastuzumab deruxtecan nxki, Trastuzumab deruxtecan-nxki', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Osteosarcoma (EFO_0000637), Breast Cancer (MONDO_0007254), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616), Colorectal Cancer (MONDO_0005575), Gastric Adenocarcinoma (EFO_0000503), Colorectal Neoplasm (EFO_0004142), Non-Small Cell Lung Carcinoma (EFO_0003060), Digestive System Neoplasm (EFO_0008549), Metastasis (EFO_0009708), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5707', 'drugName': 'Trastuzumab', 'tradeNames_string': 'Herceptin, Kadcyla', 'drugSynonyms_string': '4D5V8, ABP 980, ABP-980, ABP980, Abp-980 (trastuzumab biosimilar), Bmab-200, Canhera, DMB-3111 (TRASTUZUMAB BIOSIMILAR), Dmb-3111, EG-12014, EG12014, Eg-12014 (trastuzumab biosimilar), Eg12014 trastuzumab biosimilar, HLX-02, Herzuma, Hlx 02, Hlx-02 trastuzumab biosimilar, Hlx02, Kanjinti, Ogivri, Ontruzant, Pf-05280014, R-597, RO-0452317, RO0452317, Rhumab her2, SYD-977, SYD977, Sb-3 (trastuzumab biosimilar), Trastuzumab, Trastuzumab (herceptin), Trastuzumab anns, Trastuzumab beta, Trastuzumab biosimilar (abp-980), Trastuzumab dkst, Trastuzumab dttb, Trastuzumab pkrb, Trastuzumab qyyp, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pfizer, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-zzxf, Trazimera, Zercepac', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Non-Hodgkins Lymphoma (EFO_0005952), Somatostatinoma (EFO_1001187), Breast Ductal Adenocarcinoma (EFO_0006318), Vaginal Cancer (MONDO_0001402), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Endometrial Cancer (MONDO_0011962), Angiosarcoma (EFO_0003968), Pericardial Effusion (MONDO_0001370), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Breast Carcinoma (EFO_0000305), Ovarian Cancer (MONDO_0008170), Vulva Cancer (MONDO_0001528), Breast Neoplasm (EFO_0003869), Gastric Cancer (MONDO_0001056), Prostate Cancer (MONDO_0008315), Insulinoma (EFO_0000549), Malignant Tumor Of Parathyroid Gland (MONDO_0021311), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Colorectal Neoplasm (EFO_0004142), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Mycosis Fungoides (EFO_1001051), Pleural Effusion (EFO_0009637), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Endometrial Carcinoma (EFO_1001512), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Appendix Carcinoma (MONDO_0003196), Gallbladder Cancer (MONDO_0005411), Malignant Testicular Germ Cell Tumor (MONDO_0003510), Urinary Bladder Carcinoma (MONDO_0004986), Salivary Gland Carcinoma (MONDO_0000521), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Ependymoma (EFO_1000028), Breast Ductal Carcinoma In Situ (EFO_0000432), Oropharyngeal Carcinoma (MONDO_0044926), Digestive System Neoplasm (EFO_0008549), Carcinoma (EFO_0000313), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Paget Disease (MONDO_0021165), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Osteosarcoma (EFO_0000637), Esophageal Squamous Cell Carcinoma (EFO_0005922), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Anus Cancer (MONDO_0001879), Head And Neck Malignant Neoplasia (EFO_0006859), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Leukemia (EFO_0000565), Lung Cancer (MONDO_0008903), Skin Disease (EFO_0000701), Stomach Neoplasm (EFO_0003897), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5757', 'drugName': 'Trastuzumab Emtansine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ado-trastuzumab emtansine, PRO-132365, RG-3502, TRASTUZUMAB-MCC-DM1 T-DM1, Trastuzumab emtansine', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616), Salivary Gland Carcinoma (MONDO_0000521), Non-Small Cell Lung Carcinoma (EFO_0003060), Salivary Gland Cancer (MONDO_0004669), Endometrial Cancer (MONDO_0011962), Metastasis (EFO_0009708), Ovarian Cancer (MONDO_0008170), Inflammatory Breast Carcinoma (EFO_1000984), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_3206', 'drugName': 'Trastuzumab Deruxtecan', 'tradeNames_string': 'Enhertu', 'drugSynonyms_string': 'DS-8201, DS-8201a, Ds-8201a, Fam-trastuzumab deruxtecan-nxki, Trastuzumab deruxtecan, Trastuzumab deruxtecan nxki, Trastuzumab deruxtecan-nxki', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Osteosarcoma (EFO_0000637), Breast Cancer (MONDO_0007254), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616), Colorectal Cancer (MONDO_0005575), Gastric Adenocarcinoma (EFO_0000503), Colorectal Neoplasm (EFO_0004142), Non-Small Cell Lung Carcinoma (EFO_0003060), Digestive System Neoplasm (EFO_0008549), Metastasis (EFO_0009708), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5756', 'drugName': 'Trastuzumab Emtansine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ado-trastuzumab emtansine, PRO-132365, RG-3502, TRASTUZUMAB-MCC-DM1 T-DM1, Trastuzumab emtansine', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616), Salivary Gland Carcinoma (MONDO_0000521), Non-Small Cell Lung Carcinoma (EFO_0003060), Salivary Gland Cancer (MONDO_0004669), Endometrial Cancer (MONDO_0011962), Metastasis (EFO_0009708), Ovarian Cancer (MONDO_0008170), Inflammatory Breast Carcinoma (EFO_1000984), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_1870', 'drugName': 'Trastuzumab Duocarmazine', 'tradeNames_string': '', 'drugSynonyms_string': 'SYD-985, SYD985, Trastuzumab duocarmazine', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Endometrium Neoplasm (MONDO_0021251), Urinary Bladder Cancer (MONDO_0001187), Triple-Negative Breast Cancer (EFO_0005537), Carcinoid Tumor (EFO_0004243), Angiosarcoma (EFO_0003968), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.129 | Q17 | What gene does the drug Doxycycline Calcium target? | The drug Doxycycline Calcium targets 4 genes: MMP7, MMP13, MMP8 and MMP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doxycycline calcium%" OR LOWER(tradeNames_string) LIKE "%doxycycline calcium%" OR LOWER(drugSynonyms_string) LIKE "%doxycycline calcium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5150', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5149', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5152', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5151', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1131 | Q17 | What gene does the drug Levamlodipine Maleate target? | The drug Levamlodipine Maleate targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levamlodipine maleate%" OR LOWER(tradeNames_string) LIKE "%levamlodipine maleate%" OR LOWER(drugSynonyms_string) LIKE "%levamlodipine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6132', 'drugName': 'Levamlodipine Maleate', 'tradeNames_string': 'Conjupri', 'drugSynonyms_string': 'Amlodipine maleate, s-, Levamlodipine maleate', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.872 | Q17 | What gene does the drug Orlistat target? | The drug Orlistat targets 2 genes: PNLIP and LIPF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%orlistat%" OR LOWER(tradeNames_string) LIKE "%orlistat%" OR LOWER(drugSynonyms_string) LIKE "%orlistat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1666', 'drugName': 'Orlistat', 'tradeNames_string': 'Alli, Beacita, Xenical', 'drugSynonyms_string': 'Lipstatin, NSC-758881, Orlipastat, Orlistat, RO 18-0647/002, RO-180647-002, RO-180647002, Tetrahydrolipstatin', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Infertility (EFO_0000545), Obesity (EFO_0001073), Hyperlipoproteinemia Type 1 (Orphanet_411), Metabolic Syndrome (EFO_0000195)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LIPF (ENSG00000182333), PNLIP (ENSG00000175535)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1667', 'drugName': 'Orlistat', 'tradeNames_string': 'Alli, Beacita, Xenical', 'drugSynonyms_string': 'Lipstatin, NSC-758881, Orlipastat, Orlistat, RO 18-0647/002, RO-180647-002, RO-180647002, Tetrahydrolipstatin', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Infertility (EFO_0000545), Obesity (EFO_0001073), Hyperlipoproteinemia Type 1 (Orphanet_411), Metabolic Syndrome (EFO_0000195)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LIPF (ENSG00000182333), PNLIP (ENSG00000175535)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.360 | Q17 | What gene does the drug Bismuth Subgallate target? | The drug Bismuth Subgallate targets the gene F12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bismuth subgallate%" OR LOWER(tradeNames_string) LIKE "%bismuth subgallate%" OR LOWER(drugSynonyms_string) LIKE "%bismuth subgallate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5123', 'drugName': 'Bismuth Subgallate', 'tradeNames_string': '', 'drugSynonyms_string': 'Basic bismuth gallate, Bismuth subgallate, Gallic acid bismuth basic salt', 'linkedDiseasesDrug_string': 'Flatulence (EFO_0009669)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F12 (ENSG00000131187)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1617 | Q17 | What gene does the drug Pf-03814735 target? | The drug Pf-03814735 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: AURKB and AURKA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pf-03814735%" OR LOWER(tradeNames_string) LIKE "%pf-03814735%" OR LOWER(drugSynonyms_string) LIKE "%pf-03814735%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5510', 'drugName': 'Pf-03814735', 'tradeNames_string': '', 'drugSynonyms_string': 'PF 03814735, PF 3814735, PF-3814735, Pf-03814735', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKA (ENSG00000087586)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5511', 'drugName': 'Pf-03814735', 'tradeNames_string': '', 'drugSynonyms_string': 'PF 03814735, PF 3814735, PF-3814735, Pf-03814735', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKA (ENSG00000087586)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.689 | Q17 | What gene does the drug Theophylline target? | The drug Theophylline targets 10 genes: PDE4D, PDE3B, ADORA2B, PDE3A, PDE4B, ADORA1, PDE4A, ADORA3, PDE4C and ADORA2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%theophylline%" OR LOWER(tradeNames_string) LIKE "%theophylline%" OR LOWER(drugSynonyms_string) LIKE "%theophylline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5472', 'drugName': 'Aminophylline', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'linkedDiseasesDrug_string': 'Cardiac Arrest (EFO_0009492), Headache (HP_0002315), Asthma (MONDO_0004979), Premature Birth (EFO_0003917), Urinary Bladder Cancer (MONDO_0001187), Pulmonary Arterial Hypertension (EFO_0001361), Airway Obstruction (HP_0006536), Acute Kidney Injury (HP_0001919), Altitude Sickness (EFO_1000782)', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3799', 'drugName': 'Oxtriphylline', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_955', 'drugName': 'Theophylline Sodium Glycinate', 'tradeNames_string': 'Asbron, Synophylate', 'drugSynonyms_string': 'Bronchoparat, Englate, Glycin theophyllinate, Glytheonate, Panophylline, Theonate sodium, Theophylline sodium glycinate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_956', 'drugName': 'Theophylline Sodium Glycinate', 'tradeNames_string': 'Asbron, Synophylate', 'drugSynonyms_string': 'Bronchoparat, Englate, Glycin theophyllinate, Glytheonate, Panophylline, Theonate sodium, Theophylline sodium glycinate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2662', 'drugName': 'Theophylline Glycinate', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2663', 'drugName': 'Theophylline Glycinate', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2664', 'drugName': 'Theophylline Glycinate', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3798', 'drugName': 'Oxtriphylline', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_5470', 'drugName': 'Aminophylline', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'linkedDiseasesDrug_string': 'Cardiac Arrest (EFO_0009492), Headache (HP_0002315), Asthma (MONDO_0004979), Premature Birth (EFO_0003917), Urinary Bladder Cancer (MONDO_0001187), Pulmonary Arterial Hypertension (EFO_0001361), Airway Obstruction (HP_0006536), Acute Kidney Injury (HP_0001919), Altitude Sickness (EFO_1000782)', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4547', 'drugName': 'Theophylline', 'tradeNames_string': 'Accurbron, Aerolate, Aerolate iii, Aerolate jr, Aerolate sr, Aquaphyllin, Bronkodyl, Duraphyl, Elixicon, Elixomin, Elixophyllin, Elixophyllin sr, Labid, Lanophyllin, Lasma, Nuelin, Nuelin sa, Nuelin sa-250, Pro-vent, Quibron, Quibron-t, Quibron-t/sr, Respbid, Slo-bid, Slo-phyllin, Somophyllin-crt, Somophyllin-t, Sustaire, T-phyl, Theo-24, Theo-dur, Theobid, Theobid jr., Theochron, Theocin, Theoclear l.a.-130, Theoclear l.a.-260, Theoclear-100, Theoclear-200, Theoclear-80, Theograd, Theolair, Theolair-sr, Theolixir, Theophyl, Theophyl-225, Theophyl-sr, Theophylline, Theophylline-sr, Theovent, Uni-dur, Uniphyl, Uniphyllin continus', 'drugSynonyms_string': 'Dimethylxanthine, Doxophylline metabolite m3, NSC-2066, NSC-757346, Theophylline, Theophylline anhydrous, Theophylline melting point standard, Theophylline monohydrate, Theophylline, anhydrous, Theophylline,anhydrous', 'linkedDiseasesDrug_string': 'Pulmonary Arterial Hypertension (EFO_0001361), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Apnea (HP_0002104), Pseudohypoparathyroidism (MONDO_0019992), Acute Myeloid Leukemia (EFO_0000222), Albright Hereditary Osteodystrophy (Orphanet_665), Cardiac Arrest (EFO_0009492), Asthma (MONDO_0004979), Premature Birth (EFO_0003917), Viral Disease (EFO_0000763), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Pseudohypoparathyroidism Type 1A (MONDO_0007078), Altitude Sickness (EFO_1000782), Chronic Bronchitis (EFO_0006505), Chronic Kidney Disease (EFO_0003884), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Failure (EFO_0009686), Kidney Disease (EFO_0003086), Acute Kidney Injury (HP_0001919), Major Depressive Disorder (MONDO_0002009)', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4546', 'drugName': 'Theophylline', 'tradeNames_string': 'Accurbron, Aerolate, Aerolate iii, Aerolate jr, Aerolate sr, Aquaphyllin, Bronkodyl, Duraphyl, Elixicon, Elixomin, Elixophyllin, Elixophyllin sr, Labid, Lanophyllin, Lasma, Nuelin, Nuelin sa, Nuelin sa-250, Pro-vent, Quibron, Quibron-t, Quibron-t/sr, Respbid, Slo-bid, Slo-phyllin, Somophyllin-crt, Somophyllin-t, Sustaire, T-phyl, Theo-24, Theo-dur, Theobid, Theobid jr., Theochron, Theocin, Theoclear l.a.-130, Theoclear l.a.-260, Theoclear-100, Theoclear-200, Theoclear-80, Theograd, Theolair, Theolair-sr, Theolixir, Theophyl, Theophyl-225, Theophyl-sr, Theophylline, Theophylline-sr, Theovent, Uni-dur, Uniphyl, Uniphyllin continus', 'drugSynonyms_string': 'Dimethylxanthine, Doxophylline metabolite m3, NSC-2066, NSC-757346, Theophylline, Theophylline anhydrous, Theophylline melting point standard, Theophylline monohydrate, Theophylline, anhydrous, Theophylline,anhydrous', 'linkedDiseasesDrug_string': 'Pulmonary Arterial Hypertension (EFO_0001361), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Apnea (HP_0002104), Pseudohypoparathyroidism (MONDO_0019992), Acute Myeloid Leukemia (EFO_0000222), Albright Hereditary Osteodystrophy (Orphanet_665), Cardiac Arrest (EFO_0009492), Asthma (MONDO_0004979), Premature Birth (EFO_0003917), Viral Disease (EFO_0000763), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Pseudohypoparathyroidism Type 1A (MONDO_0007078), Altitude Sickness (EFO_1000782), Chronic Bronchitis (EFO_0006505), Chronic Kidney Disease (EFO_0003884), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Failure (EFO_0009686), Kidney Disease (EFO_0003086), Acute Kidney Injury (HP_0001919), Major Depressive Disorder (MONDO_0002009)', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_957', 'drugName': 'Theophylline Sodium Glycinate', 'tradeNames_string': 'Asbron, Synophylate', 'drugSynonyms_string': 'Bronchoparat, Englate, Glycin theophyllinate, Glytheonate, Panophylline, Theonate sodium, Theophylline sodium glycinate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3797', 'drugName': 'Oxtriphylline', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_5471', 'drugName': 'Aminophylline', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'linkedDiseasesDrug_string': 'Cardiac Arrest (EFO_0009492), Headache (HP_0002315), Asthma (MONDO_0004979), Premature Birth (EFO_0003917), Urinary Bladder Cancer (MONDO_0001187), Pulmonary Arterial Hypertension (EFO_0001361), Airway Obstruction (HP_0006536), Acute Kidney Injury (HP_0001919), Altitude Sickness (EFO_1000782)', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4548', 'drugName': 'Theophylline', 'tradeNames_string': 'Accurbron, Aerolate, Aerolate iii, Aerolate jr, Aerolate sr, Aquaphyllin, Bronkodyl, Duraphyl, Elixicon, Elixomin, Elixophyllin, Elixophyllin sr, Labid, Lanophyllin, Lasma, Nuelin, Nuelin sa, Nuelin sa-250, Pro-vent, Quibron, Quibron-t, Quibron-t/sr, Respbid, Slo-bid, Slo-phyllin, Somophyllin-crt, Somophyllin-t, Sustaire, T-phyl, Theo-24, Theo-dur, Theobid, Theobid jr., Theochron, Theocin, Theoclear l.a.-130, Theoclear l.a.-260, Theoclear-100, Theoclear-200, Theoclear-80, Theograd, Theolair, Theolair-sr, Theolixir, Theophyl, Theophyl-225, Theophyl-sr, Theophylline, Theophylline-sr, Theovent, Uni-dur, Uniphyl, Uniphyllin continus', 'drugSynonyms_string': 'Dimethylxanthine, Doxophylline metabolite m3, NSC-2066, NSC-757346, Theophylline, Theophylline anhydrous, Theophylline melting point standard, Theophylline monohydrate, Theophylline, anhydrous, Theophylline,anhydrous', 'linkedDiseasesDrug_string': 'Pulmonary Arterial Hypertension (EFO_0001361), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Apnea (HP_0002104), Pseudohypoparathyroidism (MONDO_0019992), Acute Myeloid Leukemia (EFO_0000222), Albright Hereditary Osteodystrophy (Orphanet_665), Cardiac Arrest (EFO_0009492), Asthma (MONDO_0004979), Premature Birth (EFO_0003917), Viral Disease (EFO_0000763), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Pseudohypoparathyroidism Type 1A (MONDO_0007078), Altitude Sickness (EFO_1000782), Chronic Bronchitis (EFO_0006505), Chronic Kidney Disease (EFO_0003884), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Failure (EFO_0009686), Kidney Disease (EFO_0003086), Acute Kidney Injury (HP_0001919), Major Depressive Disorder (MONDO_0002009)', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1787 | Q17 | What gene does the drug Frovatriptan Succinate target? | The drug Frovatriptan Succinate targets 2 genes: HTR1B and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%frovatriptan succinate%" OR LOWER(tradeNames_string) LIKE "%frovatriptan succinate%" OR LOWER(drugSynonyms_string) LIKE "%frovatriptan succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4361', 'drugName': 'Frovatriptan Succinate', 'tradeNames_string': 'Frova, Frovatriptan succinate', 'drugSynonyms_string': 'Frovatriptan succinate, Frovatriptan succinate hydrate, Frovelan, Miguard, NSC-760422, SB 209509 AX, SB 209509-AX, SB-209509-AX, SB-209509AX, VML 251, VML-251', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4362', 'drugName': 'Frovatriptan Succinate', 'tradeNames_string': 'Frova, Frovatriptan succinate', 'drugSynonyms_string': 'Frovatriptan succinate, Frovatriptan succinate hydrate, Frovelan, Miguard, NSC-760422, SB 209509 AX, SB 209509-AX, SB-209509-AX, SB-209509AX, VML 251, VML-251', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1467 | Q17 | What gene does the drug Arformoterol Tartrate target? | The drug Arformoterol Tartrate targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%arformoterol tartrate%" OR LOWER(tradeNames_string) LIKE "%arformoterol tartrate%" OR LOWER(drugSynonyms_string) LIKE "%arformoterol tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_440', 'drugName': 'Arformoterol Tartrate', 'tradeNames_string': 'Brovana', 'drugSynonyms_string': 'Arformoterol tartrate, Formoterol r,r-form l-tartrate', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Bronchitis (EFO_0009661), Chronic Obstructive Pulmonary Disease (EFO_0000341), Emphysema (EFO_0000464)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.212 | Q17 | What gene does the drug Sacituzumab Govitecan target? | The drug Sacituzumab Govitecan targets 2 genes: TOP1 and TACSTD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sacituzumab govitecan%" OR LOWER(tradeNames_string) LIKE "%sacituzumab govitecan%" OR LOWER(drugSynonyms_string) LIKE "%sacituzumab govitecan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4818', 'drugName': 'Sacituzumab Govitecan', 'tradeNames_string': 'Trodelvy', 'drugSynonyms_string': 'HRS7-SN38, HRS7-SN38-ANTIBODY-DRUG-CONJUGATE, IMMU-132, Sacituzumab govitecan, Sacituzumab govitecan hziy, Sacituzumab govitecan-hziy', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Urogenital Neoplasm (EFO_0003863), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Urothelial Carcinoma (EFO_0008528), Glioblastoma Multiforme (EFO_0000519), Endometrial Carcinoma (EFO_1001512), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TACSTD2 (ENSG00000184292), TOP1 (ENSG00000198900)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4819', 'drugName': 'Sacituzumab Govitecan', 'tradeNames_string': 'Trodelvy', 'drugSynonyms_string': 'HRS7-SN38, HRS7-SN38-ANTIBODY-DRUG-CONJUGATE, IMMU-132, Sacituzumab govitecan, Sacituzumab govitecan hziy, Sacituzumab govitecan-hziy', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Urogenital Neoplasm (EFO_0003863), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Urothelial Carcinoma (EFO_0008528), Glioblastoma Multiforme (EFO_0000519), Endometrial Carcinoma (EFO_1001512), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TACSTD2 (ENSG00000184292), TOP1 (ENSG00000198900)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.880 | Q17 | What gene does the drug Trilaciclib target? | The drug Trilaciclib targets 2 genes: CDK4 and CDK6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trilaciclib%" OR LOWER(tradeNames_string) LIKE "%trilaciclib%" OR LOWER(drugSynonyms_string) LIKE "%trilaciclib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_171', 'drugName': 'Trilaciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'G1T28, G1t28-1, Trilaciclib', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Small Cell Lung Carcinoma (EFO_0000702), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Angiosarcoma (EFO_0003968)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_170', 'drugName': 'Trilaciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'G1T28, G1t28-1, Trilaciclib', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Small Cell Lung Carcinoma (EFO_0000702), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Angiosarcoma (EFO_0003968)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3860', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_string': 'Cosela', 'drugSynonyms_string': 'Trilaciclib dihydrochloride', 'linkedDiseasesDrug_string': 'Small Cell Lung Carcinoma (EFO_0000702)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3859', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_string': 'Cosela', 'drugSynonyms_string': 'Trilaciclib dihydrochloride', 'linkedDiseasesDrug_string': 'Small Cell Lung Carcinoma (EFO_0000702)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.143 | Q17 | What gene does the drug Gantenerumab target? | The drug Gantenerumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene APP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gantenerumab%" OR LOWER(tradeNames_string) LIKE "%gantenerumab%" OR LOWER(drugSynonyms_string) LIKE "%gantenerumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_439', 'drugName': 'Gantenerumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Gantenerumab, R-04909832, R-1450, R04909832, R1450, RG-1450, RO-4909832 R-1450, Ro-4909832', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'APP (ENSG00000142192)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1439 | Q17 | What gene does the drug Hexylcaine Hydrochloride target? | The drug Hexylcaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hexylcaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%hexylcaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%hexylcaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_702', 'drugName': 'Hexylcaine Hydrochloride', 'tradeNames_string': 'Cyclaine', 'drugSynonyms_string': 'Hexylcaine HCl, Hexylcaine hcl, Hexylcaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1341 | Q17 | What gene does the drug Azd-4547 target? | The drug Azd-4547 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: FGFR2, FGFR1, FGFR3 and FGFR4 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd-4547%" OR LOWER(tradeNames_string) LIKE "%azd-4547%" OR LOWER(drugSynonyms_string) LIKE "%azd-4547%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3850', 'drugName': 'Azd-4547', 'tradeNames_string': '', 'drugSynonyms_string': 'ABSK-091, ABSK091, AZD-4547, Azd 4547, Azd-4547, Azd4547, KB-74810', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Squamous Cell Carcinoma (EFO_0000707), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Urothelial Carcinoma (EFO_0008528), Central Nervous System Cancer (EFO_0000326), Squamous Cell Lung Carcinoma (EFO_0000708), Gastric Cancer (MONDO_0001056)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1786 | Q17 | What gene does the drug Fludarabine Phosphate target? | The drug Fludarabine Phosphate targets 14 genes: POLD3, RRM2B, POLD1, POLE, RRM1, POLD4, POLD2, PRIM2, POLA1, RRM2, PRIM1, POLE3, POLA2 and POLE2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fludarabine phosphate%" OR LOWER(tradeNames_string) LIKE "%fludarabine phosphate%" OR LOWER(drugSynonyms_string) LIKE "%fludarabine phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2916', 'drugName': 'Fludarabine Phosphate', 'tradeNames_string': 'Fludara, Fludarabine phosphate, Oforta', 'drugSynonyms_string': "2-f-ara-amp, 2-f-araa, 2-fluoro ara-a, 2-fluorovidarabine, Fludarabine, Fludarabine 5'-monophosphate, Fludarabine monophosphate, Fludarabine phosphate, Fluradosa, NSC-118218, NSC-118218H, NSC-312887, NSC-328002", 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Vasculitis (EFO_0006803), Refractory Anemia (EFO_0003802), Malignant Colon Neoplasm (MONDO_0021063), Lymphoid Neoplasm (EFO_0001642), Diamond-Blackfan Anemia (MONDO_0015253), Acute Myelomonocytic Leukemia (EFO_0000223), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Shwachman-Diamond Syndrome (MONDO_0009833), Aplastic Anemia (HP_0001915), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Immunodeficiency (HP_0002721), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Anemia (Phenotype) (EFO_0004272), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Severe Combined Immunodeficiency (MONDO_0015974), Wiskott-Aldrich Syndrome (MONDO_0010518), Acute Erythroleukemia (EFO_0000218), Hematopoietic And Lymphoid System Neoplasm (MONDO_0002334), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Osteosarcoma (EFO_0000637), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Ewing Sarcoma (EFO_0000174), Classic Hodgkin Lymphoma (MONDO_0009348), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Lupus Nephritis (EFO_0005761), Osteopetrosis (MONDO_0017198), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Neuromyelitis Optica (EFO_0004256), Neuroepithelial Neoplasm (MONDO_0021193), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Squamous Cell Lung Carcinoma (EFO_0000708), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Beta-Thalassemia (Orphanet_848), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Myelofibrosis (MONDO_0044903), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Granulomatous Disease (MONDO_0018305), Embryonal Neoplasm (EFO_0005784), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Severe Aplastic Anemia (EFO_0006927), Thyroid Cancer (MONDO_0002108), Hodgkins Lymphoma (EFO_0000183), Metastatic Neoplasm (EFO_0009709), Prolymphocytic Leukemia (MONDO_0001023), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Hematologic Disease (EFO_0005803), Acute Monocytic Leukemia (EFO_0000221), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Bone Marrow Failure Syndrome (MONDO_0000159), Langerhans Cell Histiocytosis (EFO_1000318), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Primary Myelofibrosis (EFO_0002430), Pure Red Cell Aplasia (HP_0012410), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Hepatoblastoma (EFO_1000292), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Thalassemia (EFO_1001996), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), B-Cell Prolymphocytic Leukemia (EFO_1000102), Acute Megakaryoblastic Leukaemia (EFO_0003025), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), T-Cell Prolymphocytic Leukemia (EFO_1000560), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Graft Versus Host Disease (MONDO_0013730), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Plasma Cell Leukemia (EFO_0006475), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Erythroblastic Leukemia (EFO_1001257), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Chronic Myelomonocytic Leukemia (EFO_1001779), Cervical Carcinoma (EFO_0001061), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Refractory Anemia With Excess Blasts (EFO_0003811), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Lymphoid Leukemia (EFO_0004289), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Histiocytosis (HP_0100727), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848), POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'numberLinkedTargets': 14}, {'UUID': 'DrugGeneTargets_v2_2917', 'drugName': 'Fludarabine Phosphate', 'tradeNames_string': 'Fludara, Fludarabine phosphate, Oforta', 'drugSynonyms_string': "2-f-ara-amp, 2-f-araa, 2-fluoro ara-a, 2-fluorovidarabine, Fludarabine, Fludarabine 5'-monophosphate, Fludarabine monophosphate, Fludarabine phosphate, Fluradosa, NSC-118218, NSC-118218H, NSC-312887, NSC-328002", 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Vasculitis (EFO_0006803), Refractory Anemia (EFO_0003802), Malignant Colon Neoplasm (MONDO_0021063), Lymphoid Neoplasm (EFO_0001642), Diamond-Blackfan Anemia (MONDO_0015253), Acute Myelomonocytic Leukemia (EFO_0000223), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Shwachman-Diamond Syndrome (MONDO_0009833), Aplastic Anemia (HP_0001915), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Immunodeficiency (HP_0002721), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Anemia (Phenotype) (EFO_0004272), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Severe Combined Immunodeficiency (MONDO_0015974), Wiskott-Aldrich Syndrome (MONDO_0010518), Acute Erythroleukemia (EFO_0000218), Hematopoietic And Lymphoid System Neoplasm (MONDO_0002334), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Osteosarcoma (EFO_0000637), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Ewing Sarcoma (EFO_0000174), Classic Hodgkin Lymphoma (MONDO_0009348), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Lupus Nephritis (EFO_0005761), Osteopetrosis (MONDO_0017198), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Neuromyelitis Optica (EFO_0004256), Neuroepithelial Neoplasm (MONDO_0021193), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Squamous Cell Lung Carcinoma (EFO_0000708), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Beta-Thalassemia (Orphanet_848), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Myelofibrosis (MONDO_0044903), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Granulomatous Disease (MONDO_0018305), Embryonal Neoplasm (EFO_0005784), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Severe Aplastic Anemia (EFO_0006927), Thyroid Cancer (MONDO_0002108), Hodgkins Lymphoma (EFO_0000183), Metastatic Neoplasm (EFO_0009709), Prolymphocytic Leukemia (MONDO_0001023), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Hematologic Disease (EFO_0005803), Acute Monocytic Leukemia (EFO_0000221), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Bone Marrow Failure Syndrome (MONDO_0000159), Langerhans Cell Histiocytosis (EFO_1000318), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Primary Myelofibrosis (EFO_0002430), Pure Red Cell Aplasia (HP_0012410), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Hepatoblastoma (EFO_1000292), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Thalassemia (EFO_1001996), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), B-Cell Prolymphocytic Leukemia (EFO_1000102), Acute Megakaryoblastic Leukaemia (EFO_0003025), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), T-Cell Prolymphocytic Leukemia (EFO_1000560), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Graft Versus Host Disease (MONDO_0013730), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Plasma Cell Leukemia (EFO_0006475), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Erythroblastic Leukemia (EFO_1001257), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Chronic Myelomonocytic Leukemia (EFO_1001779), Cervical Carcinoma (EFO_0001061), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Refractory Anemia With Excess Blasts (EFO_0003811), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Lymphoid Leukemia (EFO_0004289), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Histiocytosis (HP_0100727), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848), POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'numberLinkedTargets': 14}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1575 | Q17 | What gene does the drug Dinoprostone target? | The drug Dinoprostone targets 4 genes: PTGER3, PTGER4, PTGER2 and PTGER1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dinoprostone%" OR LOWER(tradeNames_string) LIKE "%dinoprostone%" OR LOWER(drugSynonyms_string) LIKE "%dinoprostone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4965', 'drugName': 'Dinoprostone', 'tradeNames_string': 'Cervidil, Prepidil, Propess, Prostin e2', 'drugSynonyms_string': 'Dinoprostone, Dinoprostone beta-cyclodextrin clathrate, Enzaprost e, Minprostin e2, NSC-165560, NSC-196514, Prostaglandin e2, U-12,062, U-12062', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Pain (EFO_0003843), Incomplete Abortion (EFO_1001799)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGER1 (ENSG00000160951), PTGER4 (ENSG00000171522), PTGER2 (ENSG00000125384), PTGER3 (ENSG00000050628)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1865 | Q17 | What gene does the drug Desvenlafaxine target? | The drug Desvenlafaxine targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desvenlafaxine%" OR LOWER(tradeNames_string) LIKE "%desvenlafaxine%" OR LOWER(drugSynonyms_string) LIKE "%desvenlafaxine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5874', 'drugName': 'Desvenlafaxine Fumarate', 'tradeNames_string': '', 'drugSynonyms_string': 'Desvenlafaxine fumarate, Desvenlafaxine fumarate anhydrous, O-desmethylvenlafaxine fumarate', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1438', 'drugName': 'Desvenlafaxine', 'tradeNames_string': 'Desvenlafaxine, Khedezla, Pristiq', 'drugSynonyms_string': 'D-veniz, Desvenlafaxine, Mdd-xr, Newven, O-desmethylvenlafaxine, ODV', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Chronic Hepatitis C Virus Infection (EFO_0004220), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1437', 'drugName': 'Desvenlafaxine', 'tradeNames_string': 'Desvenlafaxine, Khedezla, Pristiq', 'drugSynonyms_string': 'D-veniz, Desvenlafaxine, Mdd-xr, Newven, O-desmethylvenlafaxine, ODV', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Chronic Hepatitis C Virus Infection (EFO_0004220), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_736', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugSynonyms_string': 'DVS-233, Desvenlafaxine succinate, Desvenlafaxine succinate anhydrous, Desvenlafaxine succinate hydrate, Desvenlafaxine succinate monohydrate, Dvs anhydrous, O-desmethyl venlafaxine succinate, O-desmethylvenlafaxine succinate, WY-45233, WY45233', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5873', 'drugName': 'Desvenlafaxine Fumarate', 'tradeNames_string': '', 'drugSynonyms_string': 'Desvenlafaxine fumarate, Desvenlafaxine fumarate anhydrous, O-desmethylvenlafaxine fumarate', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_735', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugSynonyms_string': 'DVS-233, Desvenlafaxine succinate, Desvenlafaxine succinate anhydrous, Desvenlafaxine succinate hydrate, Desvenlafaxine succinate monohydrate, Dvs anhydrous, O-desmethyl venlafaxine succinate, O-desmethylvenlafaxine succinate, WY-45233, WY45233', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1749 | Q17 | What gene does the drug Rofecoxib target? | The drug Rofecoxib targets the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rofecoxib%" OR LOWER(tradeNames_string) LIKE "%rofecoxib%" OR LOWER(drugSynonyms_string) LIKE "%rofecoxib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3942', 'drugName': 'Rofecoxib', 'tradeNames_string': 'Vioxx', 'drugSynonyms_string': 'M01AH02, MK-0966, MK-966, MK0966, NSC-720256, NSC-758705, Rofecoxib, TRM-201, TRM201', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Rheumatic Disease (EFO_0005755), Prostate Cancer (MONDO_0008315), Osteoarthritis (MONDO_0005178), Colorectal Adenoma (EFO_0005406), Pain (EFO_0003843), Non-Small Cell Lung Carcinoma (EFO_0003060), Osteoarthritis, Knee (EFO_0004616), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Arthropathy (HP_0003040), Stomach Neoplasm (EFO_0003897), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.718 | Q17 | What gene does the drug Ibutilide Fumarate target? | The drug Ibutilide Fumarate targets the gene KCNH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibutilide fumarate%" OR LOWER(tradeNames_string) LIKE "%ibutilide fumarate%" OR LOWER(drugSynonyms_string) LIKE "%ibutilide fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5277', 'drugName': 'Ibutilide Fumarate', 'tradeNames_string': 'Corvert, Ibutilide fumarate', 'drugSynonyms_string': 'Ibutilide fumarate, U-70226E', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNH2 (ENSG00000055118)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1936 | Q17 | What gene does the drug Danaparoid Sodium target? | The drug Danaparoid Sodium targets the gene SERPINC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%danaparoid sodium%" OR LOWER(tradeNames_string) LIKE "%danaparoid sodium%" OR LOWER(drugSynonyms_string) LIKE "%danaparoid sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3361', 'drugName': 'Danaparoid Sodium', 'tradeNames_string': 'Orgaran', 'drugSynonyms_string': 'Danaparoid, Danaparoid sodium, ORG 10172, ORG-10172, Sodium danaparoid', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Thrombocytopenia (HP_0001873)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.852 | Q17 | What gene does the drug Polatuzumab Vedotin target? | The drug Polatuzumab Vedotin targets 16 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, CD79B, TUBB4A, TUBB6, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%polatuzumab vedotin%" OR LOWER(tradeNames_string) LIKE "%polatuzumab vedotin%" OR LOWER(drugSynonyms_string) LIKE "%polatuzumab vedotin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_560', 'drugName': 'Polatuzumab Vedotin', 'tradeNames_string': 'Polivy', 'drugSynonyms_string': 'ACD-79B-VCMMAE, ACD-79BVCMMAE, ACD79B-VCMMAE, Anti-cd79b adc, DCDS-4501A, DCDS4501A, FCU-2711, FCU2711, Polatuzumab vedotin, Polatuzumab vedotin piiq, Polatuzumab vedotin-piiq, RG-7596, RG7596, RO-5541077-000, RO-5541077000, RO5541077-000', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Non-Hodgkins Lymphoma (EFO_0005952), Neoplasm Of Mature B-Cells (EFO_0000096), Neoplasm (EFO_0000616), Lymphoma (EFO_0000574), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_561', 'drugName': 'Polatuzumab Vedotin', 'tradeNames_string': 'Polivy', 'drugSynonyms_string': 'ACD-79B-VCMMAE, ACD-79BVCMMAE, ACD79B-VCMMAE, Anti-cd79b adc, DCDS-4501A, DCDS4501A, FCU-2711, FCU2711, Polatuzumab vedotin, Polatuzumab vedotin piiq, Polatuzumab vedotin-piiq, RG-7596, RG7596, RO-5541077-000, RO-5541077000, RO5541077-000', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Non-Hodgkins Lymphoma (EFO_0005952), Neoplasm Of Mature B-Cells (EFO_0000096), Neoplasm (EFO_0000616), Lymphoma (EFO_0000574), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1938 | Q17 | What gene does the drug Zolmitriptan target? | The drug Zolmitriptan targets 2 genes: HTR1B and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zolmitriptan%" OR LOWER(tradeNames_string) LIKE "%zolmitriptan%" OR LOWER(drugSynonyms_string) LIKE "%zolmitriptan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6019', 'drugName': 'Zolmitriptan', 'tradeNames_string': 'Zolmitriptan, Zomig, Zomig-zmt', 'drugSynonyms_string': '311-C-90, 311C90, Cvt-427, NSC-760383, Zolmitriptan', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6020', 'drugName': 'Zolmitriptan', 'tradeNames_string': 'Zolmitriptan, Zomig, Zomig-zmt', 'drugSynonyms_string': '311-C-90, 311C90, Cvt-427, NSC-760383, Zolmitriptan', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.11 | Q17 | What gene does the drug Sibutramine target? | The drug Sibutramine targets 3 genes: SLC6A4, SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sibutramine%" OR LOWER(tradeNames_string) LIKE "%sibutramine%" OR LOWER(drugSynonyms_string) LIKE "%sibutramine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5637', 'drugName': 'Sibutramine', 'tradeNames_string': 'Reductil', 'drugSynonyms_string': 'Butramin, Cf-alli, Medaria, Racemic sibutramine, Sibutramine', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2809', 'drugName': 'Sibutramine Hydrochloride', 'tradeNames_string': 'Meridia', 'drugSynonyms_string': 'BTS 54524, BTS-54524, NSC-758928, Sibutramine hcl, Sibutramine hydrochloride, Sibutramine hydrochloride civ, Sibutramine hydrochloride hydrate, Sibutramine hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1695 | Q17 | What gene does the drug Naloxegol Oxalate target? | The drug Naloxegol Oxalate targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naloxegol oxalate%" OR LOWER(tradeNames_string) LIKE "%naloxegol oxalate%" OR LOWER(drugSynonyms_string) LIKE "%naloxegol oxalate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_264', 'drugName': 'Naloxegol Oxalate', 'tradeNames_string': 'Movantik', 'drugSynonyms_string': 'AZ13337019 oxalate, NKTR-118 oxalate, Naloxegol oxalate', 'linkedDiseasesDrug_string': 'Constipation Disorder (MONDO_0002203), Pain (EFO_0003843)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1124 | Q17 | What gene does the drug Somatropin target? | The drug Somatropin targets the gene GHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%somatropin%" OR LOWER(tradeNames_string) LIKE "%somatropin%" OR LOWER(drugSynonyms_string) LIKE "%somatropin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5635', 'drugName': 'Somatropin', 'tradeNames_string': 'Accretropin, Asellacrin 10, Asellacrin 2, Bio-tropin, Crescormon, Genotropin, Genotropin [Rdna Origin], Genotropin goquick, Genotropin kabipen, Genotropin kabiquick, Genotropin kabivial, Genotropin miniquick, Genotropin preservative free, Humatrope, Humatropen, Norditropin, Norditropin flexpro, Norditropin nordiflex, Norditropin penset, Norditropin simplexx, Nutropin, Nutropin aq, Nutropin aq nuspin, Nutropin aq pen, Nutropin depot, Nutropinaq, Omnitrope, Omnitrope pen 10, Omnitrope pen 5, Omnitrope surepal 10, Omnitrope surepal 15, Omnitrope surepal 5, Saizen, Saizen click.easy, Saizen easyject, Serostim, Serostim lq, Tev-Tropin, Valtropin, Zomacton, Zorbtive', 'drugSynonyms_string': 'CB-311, DA-3002, Genotonorm, Growth hormone, Growth hormone (human), Hsb-hgh, Human growth hormone, Hypertropin, LY-137998, LY137998, R-hgh, Recombinant human growth hormone, Rh-polypeptide-7, Somatotropin, Somatotropin (human), Somatotropin human, Somatotropin human growth hormone, Somatropin, Somatropin (rdna origin), Somatropin biopartners, Somatropin for injection, Somatropin recombinant, Tev-tropin, Tevtropin, Vexxon-hgh', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Tendinopathy (EFO_1001434), Noonan Syndrome (MONDO_0018997), Hereditary Endocrine Growth Disease (MONDO_0015514), Obesity (EFO_0001073), Primary Short Bowel Syndrome (MONDO_0018241), Prader-Willi Syndrome (MONDO_0008300), Aging (GO_0007568), Endocrine System Disease (EFO_0001379), Spinal Cord Injury (EFO_1001919), Mucopolysaccharidosis Type 2 (MONDO_0010674), Crohn'S Disease (EFO_0000384), Growth Delay (HP_0001510), Fetal Growth Restriction (EFO_0000495), Spinal Muscular Atrophy (EFO_0008525), Cardiovascular Disease (EFO_0000319), Osteoarthritis, Knee (EFO_0004616), Gonadal Dysgenesis (MONDO_0001967), Albright Hereditary Osteodystrophy (Orphanet_665), Tibia Fracture (EFO_0003944), Mucopolysaccharidosis Type 6 (MONDO_0009661), Turner Syndrome (MONDO_0019499), Pituitary Dwarfism (EFO_1001109), Cachexia (HP_0004326), Sarcopenia (EFO_1000653), Infertility (EFO_0000545), Hypopituitarism (EFO_0001380), Hiv-1 Infection (EFO_0000180), Brain Injury (MONDO_0043510), Pseudohypoparathyroidism Type 1A (MONDO_0007078), Facioscapulohumeral Dystrophy (Orphanet_269), Osteogenesis Imperfecta (MONDO_0019019), Short Bowel Syndrome (MONDO_0015183), Pituitary Gland Disease (EFO_0009607), Chronic Kidney Disease (EFO_0003884), Female Infertility (EFO_0008560), Hiv Infection (EFO_0000764), Cognitive Impairment (HP_0100543), Amyotrophic Lateral Sclerosis (MONDO_0004976), Heart Failure (EFO_0003144), Burn (EFO_0009516), Hiv Wasting Syndrome (EFO_0007312), Cystic Fibrosis (MONDO_0009061), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHR (ENSG00000112964)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3230', 'drugName': 'Somatrogon', 'tradeNames_string': '', 'drugSynonyms_string': 'Ctp-somatropin fusion protein, MOD-4023, MOD4023, Mod-4023, Somatrogon, Somatropin-ctp fusion protein', 'linkedDiseasesDrug_string': 'Pituitary Dwarfism (EFO_1001109)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHR (ENSG00000112964)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2482', 'drugName': 'Lonapegsomatropin', 'tradeNames_string': 'Skytrofa, Stem-stat ortho', 'drugSynonyms_string': 'ACP-011, Lonapegsomatropin, Lonapegsomatropin tcgd, Lonapegsomatropin-tcgd, TRANSCONPEG-HGH, TransConPEG hGh, rhGH-PEG', 'linkedDiseasesDrug_string': 'Pituitary Dwarfism (EFO_1001109)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHR (ENSG00000112964)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.286 | Q17 | What gene does the drug Pimavanserin Tartrate target? | The drug Pimavanserin Tartrate targets the gene HTR2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pimavanserin tartrate%" OR LOWER(tradeNames_string) LIKE "%pimavanserin tartrate%" OR LOWER(drugSynonyms_string) LIKE "%pimavanserin tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5097', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_string': 'Nuplazid', 'drugSynonyms_string': 'ACP-103, Pimavanserin tartrate', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Alzheimer Disease (MONDO_0004975), Parkinson Disease (MONDO_0005180), Hallucinations (HP_0000738), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.817 | Q17 | What gene does the drug Fadrozole Hydrochloride target? | The drug Fadrozole Hydrochloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CYP19A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fadrozole hydrochloride%" OR LOWER(tradeNames_string) LIKE "%fadrozole hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%fadrozole hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4298', 'drugName': 'Fadrozole Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Afema, CGS 16949A, CGS-16949A, Fadrozole hcl, Fadrozole hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CYP19A1 (ENSG00000137869)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1092 | Q17 | What gene does the drug Oxaprozin Potassium target? | The drug Oxaprozin Potassium targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxaprozin potassium%" OR LOWER(tradeNames_string) LIKE "%oxaprozin potassium%" OR LOWER(drugSynonyms_string) LIKE "%oxaprozin potassium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3630', 'drugName': 'Oxaprozin Potassium', 'tradeNames_string': 'Daypro alta', 'drugSynonyms_string': 'Oxaprozin potassium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.295 | Q17 | What gene does the drug Dacomitinib target? | The drug Dacomitinib targets 3 genes: ERBB2, ERBB4 and EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dacomitinib%" OR LOWER(tradeNames_string) LIKE "%dacomitinib%" OR LOWER(drugSynonyms_string) LIKE "%dacomitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3948', 'drugName': 'Dacomitinib', 'tradeNames_string': 'Vizimpro', 'drugSynonyms_string': 'Dacomitinib, Dacomitinib hydrate, Dacomitinib monohydrate, PF-00299804-03, Pf-00299804', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4810', 'drugName': 'Dacomitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Dacomitinib, Pf-00299804', 'linkedDiseasesDrug_string': 'Brain Cancer (MONDO_0001657), Cancer (MONDO_0004992), Oral Cavity Cancer (EFO_0005570), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Penile Neoplasm (EFO_1001094), Lung Cancer (MONDO_0008903), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Brain Neoplasm (EFO_0003833), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Glioblastoma Multiforme (EFO_0000519), Carcinoma (EFO_0000313), Colorectal Carcinoma (EFO_1001951), Metastasis (EFO_0009708)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4809', 'drugName': 'Dacomitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Dacomitinib, Pf-00299804', 'linkedDiseasesDrug_string': 'Brain Cancer (MONDO_0001657), Cancer (MONDO_0004992), Oral Cavity Cancer (EFO_0005570), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Penile Neoplasm (EFO_1001094), Lung Cancer (MONDO_0008903), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Brain Neoplasm (EFO_0003833), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Glioblastoma Multiforme (EFO_0000519), Carcinoma (EFO_0000313), Colorectal Carcinoma (EFO_1001951), Metastasis (EFO_0009708)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3946', 'drugName': 'Dacomitinib', 'tradeNames_string': 'Vizimpro', 'drugSynonyms_string': 'Dacomitinib, Dacomitinib hydrate, Dacomitinib monohydrate, PF-00299804-03, Pf-00299804', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3947', 'drugName': 'Dacomitinib', 'tradeNames_string': 'Vizimpro', 'drugSynonyms_string': 'Dacomitinib, Dacomitinib hydrate, Dacomitinib monohydrate, PF-00299804-03, Pf-00299804', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4811', 'drugName': 'Dacomitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Dacomitinib, Pf-00299804', 'linkedDiseasesDrug_string': 'Brain Cancer (MONDO_0001657), Cancer (MONDO_0004992), Oral Cavity Cancer (EFO_0005570), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Penile Neoplasm (EFO_1001094), Lung Cancer (MONDO_0008903), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Brain Neoplasm (EFO_0003833), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Glioblastoma Multiforme (EFO_0000519), Carcinoma (EFO_0000313), Colorectal Carcinoma (EFO_1001951), Metastasis (EFO_0009708)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.761 | Q17 | What gene does the drug Taltirelin target? | The drug Taltirelin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%taltirelin%" OR LOWER(tradeNames_string) LIKE "%taltirelin%" OR LOWER(drugSynonyms_string) LIKE "%taltirelin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4549', 'drugName': 'Taltirelin', 'tradeNames_string': '', 'drugSynonyms_string': 'TA-0910, Taltirelin', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'TRHR (ENSG00000174417)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.633 | Q17 | What gene does the drug Pramipexole Dihydrochloride target? | The drug Pramipexole Dihydrochloride targets 3 genes: DRD3, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pramipexole dihydrochloride%" OR LOWER(tradeNames_string) LIKE "%pramipexole dihydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%pramipexole dihydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5763', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_string': 'Mirapex, Mirapex Extended Release, Mirapex er, Pramipexole dihydrochloride', 'drugSynonyms_string': 'Daquiran, PNU-98528E, Pramipexole accord, Pramipexole dihydrochloride, Pramipexole dihydrochloride anhydrous, Pramipexole dihydrochloride monohydrate, Pramipexole hydrochloride, Pramipexole hydrochloride hydrate, Pramipexole teva, SND-919CL2Y, SND919CL2Y, Sifrol', 'linkedDiseasesDrug_string': 'Restless Legs Syndrome (EFO_0004270), Amyotrophic Lateral Sclerosis (MONDO_0004976), Bipolar Disorder (MONDO_0004985), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.930 | Q17 | What gene does the drug Firategrast target? | The drug Firategrast is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: ITGB1, ITGB7 and ITGA4 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%firategrast%" OR LOWER(tradeNames_string) LIKE "%firategrast%" OR LOWER(drugSynonyms_string) LIKE "%firategrast%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2077', 'drugName': 'Firategrast', 'tradeNames_string': '', 'drugSynonyms_string': 'Firategrast, SB-683699', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB1 (ENSG00000150093), ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2078', 'drugName': 'Firategrast', 'tradeNames_string': '', 'drugSynonyms_string': 'Firategrast, SB-683699', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB1 (ENSG00000150093), ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1019 | Q17 | What gene does the drug Moexipril target? | The drug Moexipril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%moexipril%" OR LOWER(tradeNames_string) LIKE "%moexipril%" OR LOWER(drugSynonyms_string) LIKE "%moexipril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4629', 'drugName': 'Moexipril', 'tradeNames_string': '', 'drugSynonyms_string': 'Moexipril, RS-10085, Uniretic, Univasc', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Primary Biliary Cirrhosis (EFO_1001486), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_517', 'drugName': 'Moexipril Hydrochloride', 'tradeNames_string': 'Moexipril hydrochloride, Perdix, Univasc', 'drugSynonyms_string': 'CI 925, CI-925, Moexipril hcl, Moexipril hydrochloride, RS-10085-197, SPM 925, SPM-925', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.132 | Q17 | What gene does the drug Rg-1530 target? | The drug Rg-1530 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 9 genes: FGFR2, FLT3, FLT4, PLK4, FLT1, KDR, FGFR1, PDGFRB and AURKA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rg-1530%" OR LOWER(tradeNames_string) LIKE "%rg-1530%" OR LOWER(drugSynonyms_string) LIKE "%rg-1530%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2530', 'drugName': 'Rg-1530', 'tradeNames_string': '', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), AURKA (ENSG00000087586), PLK4 (ENSG00000142731)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2528', 'drugName': 'Rg-1530', 'tradeNames_string': '', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), AURKA (ENSG00000087586), PLK4 (ENSG00000142731)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2526', 'drugName': 'Rg-1530', 'tradeNames_string': '', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), AURKA (ENSG00000087586), PLK4 (ENSG00000142731)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2525', 'drugName': 'Rg-1530', 'tradeNames_string': '', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), AURKA (ENSG00000087586), PLK4 (ENSG00000142731)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2531', 'drugName': 'Rg-1530', 'tradeNames_string': '', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), AURKA (ENSG00000087586), PLK4 (ENSG00000142731)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2529', 'drugName': 'Rg-1530', 'tradeNames_string': '', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), AURKA (ENSG00000087586), PLK4 (ENSG00000142731)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2527', 'drugName': 'Rg-1530', 'tradeNames_string': '', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), AURKA (ENSG00000087586), PLK4 (ENSG00000142731)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1175 | Q17 | What gene does the drug Pomalidomide target? | The drug Pomalidomide targets 4 genes: RBX1, CRBN, DDB1 and CUL4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pomalidomide%" OR LOWER(tradeNames_string) LIKE "%pomalidomide%" OR LOWER(drugSynonyms_string) LIKE "%pomalidomide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4886', 'drugName': 'Pomalidomide', 'tradeNames_string': 'Imnovid, Pomalyst', 'drugSynonyms_string': 'Actimid, CC-4047, IMID 3, IMID-3, Pomalidomide', 'linkedDiseasesDrug_string': "Asymptomatic Myeloma (EFO_0003073), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Primary Myelofibrosis (EFO_0002430), Medulloblastoma (EFO_0002939), Al Amyloidosis (MONDO_0019438), Graft Versus Host Disease (MONDO_0013730), Plasmacytoma (EFO_0006738), Burkitts Lymphoma (EFO_0000309), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Plasma Cell Leukemia (EFO_0006475), Polycythemia Vera (EFO_0002429), Prostate Cancer (MONDO_0008315), Myelofibrosis (MONDO_0044903), Interstitial Lung Disease (EFO_0004244), Diffuse Large B-Cell Lymphoma (EFO_0000403), Immune System Disease (EFO_0000540), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Sickle Cell Anemia (MONDO_0011382), Soft Tissue Sarcoma (EFO_1001968), Waldenstrom Macroglobulinemia (EFO_0009441), Castleman Disease (MONDO_0015564), Systemic Scleroderma (EFO_0000717), Hodgkins Lymphoma (EFO_0000183), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Kaposi'S Sarcoma (EFO_0000558), Primary Systemic Amyloidosis (MONDO_0017816), Pulmonary Fibrosis (EFO_0009448)", 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CRBN (ENSG00000113851), DDB1 (ENSG00000167986), CUL4A (ENSG00000139842), RBX1 (ENSG00000100387)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.327 | Q17 | What gene does the drug Biciromab Brallobarbital target? | The drug Biciromab Brallobarbital is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FGB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%biciromab brallobarbital%" OR LOWER(tradeNames_string) LIKE "%biciromab brallobarbital%" OR LOWER(drugSynonyms_string) LIKE "%biciromab brallobarbital%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5505', 'drugName': 'Biciromab Brallobarbital', 'tradeNames_string': 'Fibriscint', 'drugSynonyms_string': 'Biciromab brallobarbital, T2G1S', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGB (ENSG00000171564)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1279 | Q17 | What gene does the drug Inotersen Sodium target? | The drug Inotersen Sodium targets the gene TTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inotersen sodium%" OR LOWER(tradeNames_string) LIKE "%inotersen sodium%" OR LOWER(drugSynonyms_string) LIKE "%inotersen sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3256', 'drugName': 'Inotersen Sodium', 'tradeNames_string': 'Tegsedi', 'drugSynonyms_string': 'Inotersen sodium', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Familial Amyloid Neuropathy (EFO_0004129), Polyneuropathy (EFO_0009562)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1385 | Q17 | What gene does the drug Narsoplimab target? | The drug Narsoplimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MASP2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%narsoplimab%" OR LOWER(tradeNames_string) LIKE "%narsoplimab%" OR LOWER(drugSynonyms_string) LIKE "%narsoplimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2033', 'drugName': 'Narsoplimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Masp-2 antibody, Narsoplimab, OMS-721, OMS00620646, OMS620646, OMS721', 'linkedDiseasesDrug_string': 'Iga Glomerulonephritis (EFO_0004194), Lupus Nephritis (EFO_0005761), Covid-19 (MONDO_0100096), Atypical Hemolytic-Uremic Syndrome (MONDO_0016244)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MASP2 (ENSG00000009724)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.951 | Q17 | What gene does the drug Tazemetostat Hydrobromide target? | The drug Tazemetostat Hydrobromide targets the gene EZH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tazemetostat hydrobromide%" OR LOWER(tradeNames_string) LIKE "%tazemetostat hydrobromide%" OR LOWER(drugSynonyms_string) LIKE "%tazemetostat hydrobromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4960', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_string': 'Tazverik', 'drugSynonyms_string': 'E-7438 HYDROBROMIDE, EPZ-6438 HYDROBROMIDE, EPZ-6438 MONOHYDROBROMIDE, EZ-438, EZ438, Tazemetostat hydrobromide, Tazemetostat monohydrobromide', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Small Cell Lung Carcinoma (EFO_0000702), Sarcoma (EFO_0000691)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EZH2 (ENSG00000106462)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1867 | Q17 | What gene does the drug Clonazepam target? | The drug Clonazepam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clonazepam%" OR LOWER(tradeNames_string) LIKE "%clonazepam%" OR LOWER(drugSynonyms_string) LIKE "%clonazepam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1496', 'drugName': 'Clonazepam', 'tradeNames_string': 'Clonazepam, Klonopin, Klonopin rapidly disintegrating, Rivotril', 'drugSynonyms_string': 'Clonazepam, Clonazepam civ, NSC-179913, RO 5-4023, RO-5-4023, RO-54023, Ravotril, Rivatril', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Burning Mouth Syndrome (EFO_1000850), Rem Sleep Behavior Disorder (EFO_0007462), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cannabis Dependence (EFO_0007191), Panic Disorder (EFO_0004262), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250), Status Epilepticus (EFO_0008526), Schizophrenia (MONDO_0005090), Epilepsia Partialis Continua (EFO_1000924)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1372 | Q17 | What gene does the drug Rociletinib target? | The drug Rociletinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rociletinib%" OR LOWER(tradeNames_string) LIKE "%rociletinib%" OR LOWER(drugSynonyms_string) LIKE "%rociletinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6356', 'drugName': 'Rociletinib', 'tradeNames_string': '', 'drugSynonyms_string': 'AVL-301, CNX-419, CO-1686, CS-1631, Rociletinib', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1520 | Q17 | What gene does the drug Lutetium Lu 177 Vipivotide Tetraxetan target? | The drug Lutetium Lu 177 Vipivotide Tetraxetan targets the gene FOLH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lutetium lu 177 vipivotide tetraxetan%" OR LOWER(tradeNames_string) LIKE "%lutetium lu 177 vipivotide tetraxetan%" OR LOWER(drugSynonyms_string) LIKE "%lutetium lu 177 vipivotide tetraxetan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5876', 'drugName': 'Lutetium Lu 177 Vipivotide Tetraxetan', 'tradeNames_string': 'Pluvicto', 'drugSynonyms_string': '177LU-LABELED PSMA-617, 177Lu-PSMA-617, 177lu-psma-617, Lutetium (177lu) vipivotide tetraxetan, Lutetium lu 177 vipivotide tetraxetan, Lutetium lu-177 vipivotide tetraxetan, Pluvicto, Psma-617 lu-177, Vipivotide tetraxetan lu-177, Vipivotide tetraxetan lutetium lu-177', 'linkedDiseasesDrug_string': 'Urogenital Neoplasm (EFO_0003863), Prostate Cancer (MONDO_0008315), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.702 | Q17 | What gene does the drug Xl-281 target? | The drug Xl-281 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: BRAF and RAF1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xl-281%" OR LOWER(tradeNames_string) LIKE "%xl-281%" OR LOWER(drugSynonyms_string) LIKE "%xl-281%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3694', 'drugName': 'Xl-281', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS-908662, Bms-908662 free base, EXEL-2819, Xl 281, Xl-281', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Colorectal Carcinoma (EFO_1001951), Papillary Thyroid Carcinoma (EFO_0000641), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3695', 'drugName': 'Xl-281', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS-908662, Bms-908662 free base, EXEL-2819, Xl 281, Xl-281', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Colorectal Carcinoma (EFO_1001951), Papillary Thyroid Carcinoma (EFO_0000641), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.218 | Q17 | What gene does the drug Pazopanib Hydrochloride target? | The drug Pazopanib Hydrochloride targets 11 genes: LCK, FGFR3, FLT4, KIT, FLT1, KDR, FGFR1, ITK, CSF1R, PDGFRB and PDGFRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pazopanib hydrochloride%" OR LOWER(tradeNames_string) LIKE "%pazopanib hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%pazopanib hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_390', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_392', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_388', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_386', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_385', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_391', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_389', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_387', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_string': 'Votrient', 'drugSynonyms_string': 'GW-786034B, GW786034B, Pazopanib (as hydrochloride), Pazopanib hcl, Pazopanib hydrochloride, Pazopanib monohydrochloride', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'numberLinkedTargets': 11}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1043 | Q17 | What gene does the drug Nalmefene target? | The drug Nalmefene targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nalmefene%" OR LOWER(tradeNames_string) LIKE "%nalmefene%" OR LOWER(drugSynonyms_string) LIKE "%nalmefene%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4044', 'drugName': 'Nalmefene', 'tradeNames_string': 'Selincro', 'drugSynonyms_string': 'JF-1, JKB-121, Nalmefene, Nalmefene hydrochloride dihydrate, Nalmefene hydrochloride hydrate, Nalmetrene, ORF 1167, ORF 11676, ORF-1167, ORF-11676, Revex, SRD-174, SRD174', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Atopic Eczema (EFO_0000274), Non-Alcoholic Steatohepatitis (EFO_1001249), Kidney Disease (EFO_0003086), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_705', 'drugName': 'Nalmefene Hydrochloride', 'tradeNames_string': 'Revex', 'drugSynonyms_string': 'JF-1 HYDROCHLORIDE, Nalmefene hcl, Nalmefene hydrochloride', 'linkedDiseasesDrug_string': 'Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1815 | Q17 | What gene does the drug Ibuprofen target? | The drug Ibuprofen targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_string) LIKE "%ibuprofen%" OR LOWER(drugSynonyms_string) LIKE "%ibuprofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3209', 'drugName': 'Ibuprofen', 'tradeNames_string': "Aches-n-pain, Advil, Advil liqui-gels, Advil migraine liqui-gels, Anadin joint pain, Anadin liquifast, Anadin period pain relief, Anadin ultra, Apsifen, Apsifen-f, Arthrofen 200, Arthrofen 400, Arthrofen 600, Brufen ret, Caldolor, Cap-profen, Children's advil, Children's advil-flavored, Children's elixsure, Children's ibuprofen, Children's motrin, Co-op, Codafen continus, Cuprofen for child, Cuprofen plus, Deep relief, Ebufac, Femafen, Fenbid, Fenbid fte, Fenpaed, Feverfen, Fleximex, Ibu-slo, Ibu-tab, Ibu-tab 200, Ibucalm, Ibuderm, Ibufac, Ibugel, Ibugel fte, Ibular, Ibuleve, Ibumed, Ibumetin, Ibumousse, Ibuprin, Ibuprofen, Ibuprohm, Ibuspray, Ibutime, Inabrin, Infant's advil, Inoven, Isisfen, Junifen, Junior strength advil, Junior strength ibuprofen, Junior strength motrin, Lidifen, Lidifen-f, Lobufen, Mandafen, Manorfen, Maxa-gesic, Medipren, Midol, Midol liquid gels, Migrafen, Motrin, Motrin ib, Motrin migraine pain, Novaprin, Nuprin, Nurofen 400, Nurofen back pain sr, Nurofen child, Nurofen for child, Nurofen plus, Nurofen recovery, Nurofen sinus, Nurofen solb, Orbifen, Pacifene, Paxofen, Pedea, Pediatric advil, Phensic, Phor pain, Phorpain, Phorpain max strgh, Profen, Proflex, Proflex sr, Relcofen, Rimafen, Rufen, Seclodin, Suspren, Tab-profen", 'drugSynonyms_string': 'Burana, IB-100, IP-82, Ibuprofen, Ibuprofenum, M01AE01, NSC-256857, RD 13621, U-18,573, U-18573', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Migraine Disorder (MONDO_0005277), Vasculitis (EFO_0006803), Allergic Rhinitis (EFO_0005854), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Causalgia (EFO_1000854), Malignant Glioma (MONDO_0100342), Retinopathy Of Prematurity (EFO_1001158), Neck Pain (HP_0030833), Myalgia (HP_0003326), Arthralgia (HP_0002829), Burn (EFO_0009516), Orthostatic Hypotension (EFO_0005252), Brachial Plexus Neuritis (EFO_1000843), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Dysmenorrhea (HP_0100607), Headache (HP_0002315), Acute Respiratory Distress Syndrome (EFO_1000637), Chronic Granulomatous Disease (MONDO_0018305), Peptic Ulcer (HP_0004398), Sinusitis (EFO_0007486), Cervical Spondylosis (EFO_0009610), Pharyngitis (MONDO_0002258), Duchenne Muscular Dystrophy (MONDO_0010679), Influenza (EFO_0007328), Obstructive Sleep Apnea (EFO_0003918), Hiv Infection (EFO_0000764), Pulpitis (EFO_1001139), Osteoarthritis (MONDO_0005178), Low Back Pain (HP_0003419), Alzheimer Disease (MONDO_0004975), Spondyloarthropathy (EFO_0000706), Breast Neoplasm (EFO_0003869), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Aphthous Ulcer (EFO_0003938), Osteoarthritis, Knee (EFO_0004616), Arthritis (EFO_0005856), Cardiovascular Disease (EFO_0000319), Partial Epilepsy (EFO_0004263), Periodontitis (EFO_0000649), Tibia Fracture (EFO_0003944), Patent Ductus Arteriosus (HP_0001643), Sunburn (EFO_0003958), Premature Birth (EFO_0003917), Common Cold (EFO_0007214), Fever (HP_0001945), Sprain (EFO_0009582), Ankle Fracture (EFO_0009615), Chronic Pain (HP_0012532), Tuberculosis (MONDO_0018076), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Toothache (EFO_0010072), Rheumatic Disease (EFO_0005755), Cerebral Palsy (EFO_1000632), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Malaria (EFO_0001068), Tooth Disease (EFO_1001216), Muscular Disease (EFO_0002970), Septic Shock (EFO_0006834), Emphysema (EFO_0000464), Acute Pancreatitis (EFO_1000652), Vaginal Inflammation (EFO_0005757), Enuresis (MONDO_0024290), Back Pain (HP_0003418), Rheumatoid Arthritis (EFO_0000685), Altitude Sickness (EFO_1000782), Temporomandibular Joint Disorder (EFO_0005279), Cognitive Impairment (HP_0100543), Bronchopulmonary Dysplasia (MONDO_0019091)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1446', 'drugName': 'Dexibuprofen', 'tradeNames_string': 'Seractil', 'drugSynonyms_string': '(s)-ibuprofen, Dexibuprofen, IBU-TAB, NSC-759814, Neoprofen, Rufen, S-ibuprofen', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Fever (HP_0001945), Pain (EFO_0003843)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_566', 'drugName': 'Ibuprofen Sodium', 'tradeNames_string': 'Advil, Ibuprofen sodium', 'drugSynonyms_string': 'Ibuprofen sodium, Ibuprofen sodium dihydrate, Sodium ibuprofen dihydrate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4050', 'drugName': 'Ibuprofen Lysine', 'tradeNames_string': 'Feminax express, Ibuprofen lysine, Neoprofen, Nurofen advance, Nurofen max strgth mig pain, Nurofen migraine pain, Nurofen tension headache', 'drugSynonyms_string': 'Arfen, Dolormin, Ibuprofen l-lysine, Ibuprofen lysinate, Ibuprofen lysine, Imbun, Lisiprofen, Saren, Solufenum, Soluphene', 'linkedDiseasesDrug_string': 'Patent Ductus Arteriosus (HP_0001643)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.161 | Q17 | What gene does the drug Entrectinib target? | The drug Entrectinib targets 5 genes: ALK, NTRK1, NTRK2, NTRK3 and ROS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%entrectinib%" OR LOWER(tradeNames_string) LIKE "%entrectinib%" OR LOWER(drugSynonyms_string) LIKE "%entrectinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1203', 'drugName': 'Entrectinib', 'tradeNames_string': 'Rozlytrek', 'drugSynonyms_string': 'Entrectinib, NMS-E628, RXDX-101, Rxdx-101', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Myeloid Leukemia (EFO_0000222), Central Nervous System Cancer (EFO_0000326), Cutaneous Melanoma (EFO_0000389), Invasive Lobular Carcinoma (EFO_0000553)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_1204', 'drugName': 'Entrectinib', 'tradeNames_string': 'Rozlytrek', 'drugSynonyms_string': 'Entrectinib, NMS-E628, RXDX-101, Rxdx-101', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Myeloid Leukemia (EFO_0000222), Central Nervous System Cancer (EFO_0000326), Cutaneous Melanoma (EFO_0000389), Invasive Lobular Carcinoma (EFO_0000553)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_1205', 'drugName': 'Entrectinib', 'tradeNames_string': 'Rozlytrek', 'drugSynonyms_string': 'Entrectinib, NMS-E628, RXDX-101, Rxdx-101', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Myeloid Leukemia (EFO_0000222), Central Nervous System Cancer (EFO_0000326), Cutaneous Melanoma (EFO_0000389), Invasive Lobular Carcinoma (EFO_0000553)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1059 | Q17 | What gene does the drug Alendronate Sodium target? | The drug Alendronate Sodium targets the gene FDPS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alendronate sodium%" OR LOWER(tradeNames_string) LIKE "%alendronate sodium%" OR LOWER(drugSynonyms_string) LIKE "%alendronate sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4741', 'drugName': 'Alendronate Sodium', 'tradeNames_string': 'Alendronate sodium, Binosto, Fosamax', 'drugSynonyms_string': 'Adrovance, Alendronate (as sodium), Alendronate sodium, Alendronate sodium hydrate, Alendronate sodium trihydrate, Alendronic acid monosodium salt trihydrate, Fosavance, G-704,650, G-704650, MK-217, NSC-722597, NSC-758931, Sodium alendronate, Sodium alendronate trihydrate, Vantavo', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Postmenopausal Osteoporosis (EFO_0003854), Breast Cancer (MONDO_0007254), Vitamin D Deficiency (EFO_0003762), Osteitis Deformans (EFO_0004261), Metabolic Disease (EFO_0000589)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1243 | Q17 | What gene does the drug Abelacimab target? | The drug Abelacimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene F11. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abelacimab%" OR LOWER(tradeNames_string) LIKE "%abelacimab%" OR LOWER(drugSynonyms_string) LIKE "%abelacimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2293', 'drugName': 'Abelacimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Abelacimab', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'F11 (ENSG00000088926)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.641 | Q17 | What gene does the drug Amg-319 target? | The drug Amg-319 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PIK3CD. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amg-319%" OR LOWER(tradeNames_string) LIKE "%amg-319%" OR LOWER(drugSynonyms_string) LIKE "%amg-319%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4652', 'drugName': 'Amg-319', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG319, Amg-319, J3.391.906I', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Mantle Cell Lymphoma (EFO_1001469), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.522 | Q17 | What gene does the drug Eszopiclone target? | The drug Eszopiclone targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eszopiclone%" OR LOWER(tradeNames_string) LIKE "%eszopiclone%" OR LOWER(drugSynonyms_string) LIKE "%eszopiclone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5294', 'drugName': 'Eszopiclone', 'tradeNames_string': 'Eszopiclone, Lunesta', 'drugSynonyms_string': '(S)-ZOPICLONE, (S)-Zopiclone, Estorra, Eszopiclon, Eszopiclone, Eszopiclone civ, GSK-1755165, Zopiclone s-form', 'linkedDiseasesDrug_string': 'Generalized Anxiety Disorder (EFO_1001892), Cannabis Dependence (EFO_0007191), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1624 | Q17 | What gene does the drug Doxacurium Chloride target? | The drug Doxacurium Chloride targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doxacurium chloride%" OR LOWER(tradeNames_string) LIKE "%doxacurium chloride%" OR LOWER(drugSynonyms_string) LIKE "%doxacurium chloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5531', 'drugName': 'Doxacurium Chloride', 'tradeNames_string': 'Nuromax', 'drugSynonyms_string': 'BW A938U DICHLORIDE, BW-A938U, Doxacurium chloride, Doxacurium chloride, meso-, Meso doxacurium chloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1522 | Q17 | What gene does the drug Anakinra target? | The drug Anakinra targets the gene IL1R1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anakinra%" OR LOWER(tradeNames_string) LIKE "%anakinra%" OR LOWER(drugSynonyms_string) LIKE "%anakinra%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2379', 'drugName': 'Anakinra', 'tradeNames_string': 'Antril, Kineret', 'drugSynonyms_string': 'AMG-719, Alta-2530, Alta2530, Anakinra, Interleukin-1 receptor antagonist anakinra, Osp-101', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Asymptomatic Myeloma (EFO_0003073), Multiple Myeloma (EFO_0001378), Chronic Lymphocytic Leukemia (EFO_0000095), Pulmonary Hypertension (MONDO_0005149), Pneumonia (EFO_0003106), Multiple Sclerosis (MONDO_0005301), Infection (EFO_0000544), Macrophage Activation Syndrome (EFO_1001806), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), Adult-Onset Still'S Disease (EFO_0007135), Hypoglycemia (HP_0001943), Temporal Arteritis (EFO_1001209), Hepatitis, Alcoholic (EFO_1001345), Polycystic Ovary Syndrome (EFO_0000660), Uveitis (EFO_1001231), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Intracerebral Hemorrhage (EFO_0005669), Blepharitis (EFO_0009536), Juvenile Idiopathic Arthritis (EFO_0002609), Cinca Syndrome (MONDO_0011776), Allergic Contact Dermatitis (EFO_1000668), Hearing Loss (EFO_0004238), Acute Myocardial Infarction (EFO_0008583), Endometriosis (EFO_0001065), Knee Injury (EFO_0009507), Inclusion Body Myositis (EFO_0007323), Chronic Granulomatous Disease (MONDO_0018305), Dermatomyositis (EFO_0000398), Immune System Disease (EFO_0000540), Familial Mediterranean Fever (MONDO_0018088), Pancreatic Carcinoma (EFO_0002618), Asthma (MONDO_0004979), Neoplasm Of Mature B-Cells (EFO_0000096), Inner Ear Disease (EFO_0009672), Brain Injury (MONDO_0043510), Influenza (EFO_0007328), Rheumatoid Arthritis (EFO_0000685), Chronic Fatigue Syndrome (EFO_0004540), Gout (EFO_0004274), Sarcoidosis (MONDO_0019338), Rectum Cancer (EFO_1000657), Mucocutaneous Lymph Node Syndrome (EFO_0004246), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Osteoarthritis (MONDO_0005178), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Pericarditis (EFO_0007427), Metabolic Syndrome (EFO_0000195), Type 1 Diabetes Mellitus (MONDO_0005147), Myocarditis (EFO_0009609), Hidradenitis Suppurativa (EFO_1000710), Severe Acute Respiratory Syndrome (EFO_0000694), Familial Cold Urticaria (Orphanet_47045)", 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL1R1 (ENSG00000115594)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.604 | Q17 | What gene does the drug Finerenone target? | The drug Finerenone targets the gene NR3C2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%finerenone%" OR LOWER(tradeNames_string) LIKE "%finerenone%" OR LOWER(drugSynonyms_string) LIKE "%finerenone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_365', 'drugName': 'Finerenone', 'tradeNames_string': 'Kerendia', 'drugSynonyms_string': 'BAY 94-8862, BAY-94-8862, Bay94-8862, Finerenone', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Diabetic Nephropathy (EFO_0000401)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.198 | Q17 | What gene does the drug Pentoxifylline target? | The drug Pentoxifylline targets 25 genes: PDE6D, PDE9A, PDE6H, PDE4D, ADORA2B, PDE4B, PDE1B, PDE6B, PDE6A, PDE5A, PDE10A, PDE1A, PDE8A, PDE2A, PDE6G, PDE4C, PDE7A, PDE3A, ADORA2A, PDE7B, PDE1C, PDE3B, PDE4A, PDE6C and PDE8B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentoxifylline%" OR LOWER(tradeNames_string) LIKE "%pentoxifylline%" OR LOWER(drugSynonyms_string) LIKE "%pentoxifylline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4263', 'drugName': 'Pentoxifylline', 'tradeNames_string': 'Neotren mr, Pentoxifylline, Pentoxil, Trental, Trental 100, Trental 400', 'drugSynonyms_string': 'BL 191, BL-191, C04AD03, NSC-637086, NSC-758481, Oxpentifylline, Oxypentifylline, Pentoxifylline, Pentoxiphyllin', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Fibrosis (EFO_0006890), Plasmodium Falciparum Malaria (EFO_0007444), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Hepatic Failure (HP_0001399), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Glomerulonephritis (MONDO_0002462), Avascular Necrosis (MONDO_0018373), Injury (EFO_0000546), Primary Biliary Cirrhosis (EFO_1001486), Hepatitis, Alcoholic (EFO_1001345), Breast Neoplasm (EFO_0003869), Nephrotic Syndrome (EFO_0004255), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Non-Alcoholic Steatohepatitis (EFO_1001249), Cardiovascular Disease (EFO_0000319), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Coronary Syndrome (EFO_0005672), Endometriosis (EFO_0001065), Necrotizing Enterocolitis (EFO_0003928), Patent Ductus Arteriosus (HP_0001643), Acute Pancreatitis (EFO_1000652), Central Nervous System Neoplasm (EFO_1000158), Biliary Atresia (MONDO_0008867), Leishmaniasis (EFO_0005044), Anemia (Phenotype) (EFO_0004272), Pulmonary Sarcoidosis (DOID_13406), Duchenne Muscular Dystrophy (MONDO_0010679), Infertility (EFO_0000545), Neonatal Sepsis (HP_0040187), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Hepatopulmonary Syndrome (EFO_1001346), Hepatic Steatosis (HP_0001397), Pancreatitis (EFO_0000278), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Diabetic Nephropathy (EFO_0000401), Non-Small Cell Lung Carcinoma (EFO_0003060), Cutaneous Leishmaniasis (EFO_0005046), Acute Kidney Injury (HP_0001919), Major Depressive Disorder (MONDO_0002009), Brachial Plexus Neuropathy (EFO_1000844), Schizophrenia (MONDO_0005090), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'numberLinkedTargets': 25}, {'UUID': 'DrugGeneTargets_v2_4264', 'drugName': 'Pentoxifylline', 'tradeNames_string': 'Neotren mr, Pentoxifylline, Pentoxil, Trental, Trental 100, Trental 400', 'drugSynonyms_string': 'BL 191, BL-191, C04AD03, NSC-637086, NSC-758481, Oxpentifylline, Oxypentifylline, Pentoxifylline, Pentoxiphyllin', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Coronary Artery Disease (EFO_0001645), Fibrosis (EFO_0006890), Plasmodium Falciparum Malaria (EFO_0007444), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Hepatic Failure (HP_0001399), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Glomerulonephritis (MONDO_0002462), Avascular Necrosis (MONDO_0018373), Injury (EFO_0000546), Primary Biliary Cirrhosis (EFO_1001486), Hepatitis, Alcoholic (EFO_1001345), Breast Neoplasm (EFO_0003869), Nephrotic Syndrome (EFO_0004255), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Non-Alcoholic Steatohepatitis (EFO_1001249), Cardiovascular Disease (EFO_0000319), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Coronary Syndrome (EFO_0005672), Endometriosis (EFO_0001065), Necrotizing Enterocolitis (EFO_0003928), Patent Ductus Arteriosus (HP_0001643), Acute Pancreatitis (EFO_1000652), Central Nervous System Neoplasm (EFO_1000158), Biliary Atresia (MONDO_0008867), Leishmaniasis (EFO_0005044), Anemia (Phenotype) (EFO_0004272), Pulmonary Sarcoidosis (DOID_13406), Duchenne Muscular Dystrophy (MONDO_0010679), Infertility (EFO_0000545), Neonatal Sepsis (HP_0040187), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Hepatopulmonary Syndrome (EFO_1001346), Hepatic Steatosis (HP_0001397), Pancreatitis (EFO_0000278), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Diabetic Nephropathy (EFO_0000401), Non-Small Cell Lung Carcinoma (EFO_0003060), Cutaneous Leishmaniasis (EFO_0005046), Acute Kidney Injury (HP_0001919), Major Depressive Disorder (MONDO_0002009), Brachial Plexus Neuropathy (EFO_1000844), Schizophrenia (MONDO_0005090), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'numberLinkedTargets': 25}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1644 | Q17 | What gene does the drug Egaptivon Pegol target? | The drug Egaptivon Pegol is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene VWF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%egaptivon pegol%" OR LOWER(tradeNames_string) LIKE "%egaptivon pegol%" OR LOWER(drugSynonyms_string) LIKE "%egaptivon pegol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2933', 'drugName': 'Egaptivon Pegol', 'tradeNames_string': '', 'drugSynonyms_string': 'ARC-1779, ARC1779, Arc1779, Egaptivon pegol', 'linkedDiseasesDrug_string': 'Thrombotic Disease (MONDO_0000831), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Von Willebrand Disease (Orphanet_903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'VWF (ENSG00000110799)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.961 | Q17 | What gene does the drug Lutropin Alfa target? | The drug Lutropin Alfa targets the gene LHCGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lutropin alfa%" OR LOWER(tradeNames_string) LIKE "%lutropin alfa%" OR LOWER(drugSynonyms_string) LIKE "%lutropin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_671', 'drugName': 'Lutropin Alfa', 'tradeNames_string': 'Luveris', 'drugSynonyms_string': 'ATC G03 GA GONADOTROPINS, Luteinising hormone, Luteinising hormone (human), Lutropin alfa', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Female Infertility (EFO_0008560), Infertility (EFO_0000545)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LHCGR (ENSG00000138039)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.416 | Q17 | What gene does the drug Norepinephrine Bitartrate target? | The drug Norepinephrine Bitartrate targets 9 genes: ADRA2A, ADRB1, ADRA2C, ADRA1A, ADRA1D, ADRA1B, ADRB3, ADRA2B and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%norepinephrine bitartrate%" OR LOWER(tradeNames_string) LIKE "%norepinephrine bitartrate%" OR LOWER(drugSynonyms_string) LIKE "%norepinephrine bitartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1843', 'drugName': 'Norepinephrine Bitartrate', 'tradeNames_string': 'Adrenor, Aktamin, Levarterenol Bitartrate, Levophed, Noradrenaline, Norepinephrine bitartrate, Norepinephrine bitartrate in 5% dextrose', 'drugSynonyms_string': 'Aktamin, Arterenol, tartrate, monohydrate, Binodrenal, Levarterenol bitartrate, NSC-169106, Noradrenaline, Noradrenaline (as tartrate), Noradrenaline bitartrate, Noradrenaline tartrate, Norepinephrine, Norepinephrine bitartrate, Norepinephrine bitartrate monohydrate, Norepinephrine d-bitartrate, Norepinephrine hydrochloride', 'linkedDiseasesDrug_string': 'Acute Hypotension (EFO_0002497), Sepsis (HP_0100806), Acute Lung Injury (EFO_0004610), Ischemic Stroke (HP_0002140), Poliomyelitis (EFO_0007450), Cardiovascular Disease (EFO_0000319), Renal Insufficiency (HP_0000083), Hypotension (EFO_0005251)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.99 | Q17 | What gene does the drug Eptacog Alfa target? | The drug Eptacog Alfa is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene F7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eptacog alfa%" OR LOWER(tradeNames_string) LIKE "%eptacog alfa%" OR LOWER(drugSynonyms_string) LIKE "%eptacog alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2829', 'drugName': 'Eptacog Alfa (Activated)', 'tradeNames_string': '', 'drugSynonyms_string': 'Eptacog alfa (activated), Eptacog beta (activated), LR-769, LR769', 'linkedDiseasesDrug_string': 'Hemophilia B (MONDO_0010604), Intracerebral Hemorrhage (EFO_0005669), Hemorrhagic Disease (MONDO_0002243), Hemophilia A (MONDO_0010602), Factor Vii Deficiency (MONDO_0002244)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F7 (ENSG00000057593)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_475', 'drugName': 'Eptacog Alfa', 'tradeNames_string': '', 'drugSynonyms_string': 'Eptacog alfa, Eptacog alfa (activated), Eptacog beta (activated), LR-769, LR769', 'linkedDiseasesDrug_string': 'Hemophilia B (MONDO_0010604), Hemophilia A (MONDO_0010602), Factor Vii Deficiency (MONDO_0002244)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'F7 (ENSG00000057593)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3250', 'drugName': 'Eptacog Alfa Pegol (Activated)', 'tradeNames_string': '', 'drugSynonyms_string': 'Activated recombinant human factor vii, long acting, Eptacog alfa pegol (activated)', 'linkedDiseasesDrug_string': 'Hemophilia B (MONDO_0010604), Hemophilia A (MONDO_0010602)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'F7 (ENSG00000057593)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.988 | Q17 | What gene does the drug Piclozotan target? | The drug Piclozotan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTR1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%piclozotan%" OR LOWER(tradeNames_string) LIKE "%piclozotan%" OR LOWER(drugSynonyms_string) LIKE "%piclozotan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3853', 'drugName': 'Piclozotan', 'tradeNames_string': '', 'drugSynonyms_string': 'Piclozotan, SUN-N-4057, Sun-n4057', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.